2023 SAPA-GP Annual Conference

March 31st - April 1st, 2023

Sheraton Valley Forge Hotel

480 N Gulph Rd, King of Prussia, PA 19406

SAPA
美中藥協
Philadelphia 費城
sapagp.org

BIOPHARMA 2.0

EMBRACING NEW TECHNOLOGIES IN A CHANGING WORLD

A WELCOME LETTER FROM CONFERENCE CO-CHAIRS

Dear SAPA-GP Members, Volunteers, and Friends,

It is our great pleasure to welcome you to the 2023 Annual Conference of the Sino-American Pharmaceutical Professionals Association – Greater Philadelphia (SAPA-GP). This is an exciting opportunity to bring all of us together and celebrate our achievements as a vibrant community.

Last year, we set two big goals: to recover from the impacts of the COVID 19 pandemic, and to enhance the stature of SAPA-GP in the pharma/biotech and life science ecosystems in the Greater Philadelphia area. We are proud to say that we have accomplished both goals.

The inaugural 2022 @Philly Cell and Gene Therapy Conference was a resounding success, attracting over 500 attendees and garnering coverages from influential news outlets such as Bloomberg, AP News, Yahoo, and the NIH website. This event brought together key stakeholders and showcased the world-leading CGT ecosystem in the Greater Philadelphia area. It provided an ideal platform for innovators, business leaders, service providers, policy makers, and investors to connect and collaborate.

True to our mission to foster career development for our members, under the leadership of Dr. David Cragin, we organized four career webinars and one dedicated career development workshop. In addition, we hosted five business and scientific webinars featuring experts from the industry, academia, and law firms, to promote pharmaceutical knowledge. On the social front, SAPA-GP held a fall picnic for our volunteers and hosted a Lunar New Year dinner party, both of which were resounding successes. We are deeply grateful to our sponsors and volunteers for their invaluable contributions and unwavering support throughout the pandemic.

Turning to our 2023 Annual Conference, we are thrilled to announce that it will highlight the pharmaceutical industry's transformation and showcase the latest development in drug discovery, digital technologies, decentralized clinical studies as well as real-world evidence. In addition, we will explore creative business models that are thriving in the current market downturn and driving renewed investment, M&A, and partnership worldwide. This promises to be a must-attend event for anyone interested in the pharmaceutical industry.

We would like to take this opportunity to extend our heartfelt thanks to our dedicated leadership and functional teams, as well as our army of volunteers. Your unwavering efforts and commitment to our missions and visions have been instrumental in driving our success. We also want to express our gratitude to our advisors, sponsors, collaborators, speakers, and attendees of our major conferences, webinars and workshops. Your contributions and support have been invaluable in advancing our organization's goals.

Thank you again for joining us at our Annual Conference. We hope you will find it informative, inspiring, and enjoyable. Your participation is a testament to our collective commitment to making a positive impact in our industry and beyond.

Sincerely,

SAPA-GP President Office

Haichen Yang, President (2022-23)

Yang Yuan, President-Elect (2023-24)

Yongchao Su, Immediate Past President (2021-22)

SPONSORS


BIOSYSTEMS
Acro
Ambit®
GenScript
PROBIO
Medicilon
Morgan Stanley
SOLOMON KIM
FINANCIAL ADVISOR
MagStone LAW
康龙化成
PHARMARON
AlpalifeBio
LIDE
GemPharmatech
enevoyager
WuXi Biologics
Global Solution Provider
brigene
药明康德
WuXi AppTec
MCE
MedChemExpress
ASYMCHEM
Bristol Myers Squibb
Protheragen
BIODURO-SUNDIA
FRONTAGE
VL LLP | LAW
Alcyomics
LIFE SCIENCES
GREENHOUSE
INVESTMENTS
CytoEX
Scheer Partners
A Reputation for Results

SAPA-GP Annual Conference Day 1

	Drug Discovery and Development	Clinical Development and Regulatory
P.M.	Session 1: Revolutionary Nonclinical Approaches: Reducing Animal Use and Developing Alternative Models	Session 1: New Trends in Clinical Trials
	RECEPTION	
	DINNER (WITH TICKETS)	

SAPA-GP Annual Conference Day2

	Drug Discovery and Development	Clinical Development and Regulatory
A.M.	Session 2: Enabling Patient Centric Formulation Biologics Design by Pushing the Limit of Protein Concentration	Session 2: Best Practice of Co-development of Drug and Companion Diagnostics (CDx)
	Company Sponsored Lunch Sessions	
P.M.	Session 3: New Platform to Support Drug Discovery Session 4: Discovery of Drug Targets with Novel Mechanisms	Session 3: Model Informed Drug Development (MIDD) - Approaches in Lifecycle Drug Development and Regulatory Decision Making Session 4: Data Science in Accelerating Clinical Development
	RECEPTION	

MAR 31st 2023 KEYNOTE SPEECH

Business	Promoting Patient Access Using Real-World Evidence	Career Development Round Table discussion
Session 1: The Guide to Succeed in Business Development Despite IRA, Drying Capital, and Furious US/China Competition	Session 1: Health Economics and Outcomes Research	Session 1: Marketing Yourself
RECEPTION		
DINNER (WITH TICKETS)		

APRIL 1st 2023 KEYNOTE SPEECH

Business	Promoting Patient Access Using Real-World Evidence	Career Development Round Table discussion
Session 2: Investment Winter – Alternative Strategy	Session 2: Real World Data (RWD) and Real World Evidence (RWE)	Session 2: Effective Communication in Workplace
Company Sponsored Lunch Sessions		
Business	**Biopharma Compensation and Labor Law New Trends**	**Career Development Round Table discussion**
Session 3: Product Launch and Commercialization		Session 3: Transferrable Skill
Diversity & Inclusion	**Expert Insights – Technical, Legal and More**	Session 4: The Pharmaceutical Industry: What You Need to Know
Diversity, Equity and Inclusion: Awareness, Advocate and Action!		
RECEPTION		

AGENDA Friday, March 31st, 1:00 p.m.-9:00 p.m.

12:30-1:00 p.m.	Check in

Plenary Session & Keynote Presentations — Grand Ballroom

1:00-1:15 p.m.	**Opening Remarks & Welcome**
Session chair:	Haichen Yang, M.D., M.B.A., President of SAPA-GP 2022-23; Vice President, Clinical Research, Amicus Therapeutics
1:15-2:00 p.m.	**Transmission of Misfolded Proteins in Neurodegenerative Disorders** Virginia Lee, Ph.D., Professor, University of Pennsylvania
2:00-2:45 p.m.	**M&A Transactions Across the Pharmaceutical Industry** Tim Opler, Ph.D., Partner & Co-Founder, Torreya
2:45-3:15 p.m.	**Coffee Break**

Drug Discovery and Development — Grand Ballroom

Session 1: Revolutionary Nonclinical Approaches: Reducing Animal Use and Developing Alternative Models

Session chair:	Yingying Zhou, Ph.D., Senior Principal Scientist, Merck & Co.
3:15-3:45 p.m.	**'A New Age' for Reduction of Non-Human Primate Use in Drug Development** Danuta Herzyk, Ph.D., Scientific Associate Vice President, Merck & Co.
3:45-4:15 p.m.	**Next Generation Non-animal Testing Models for Early Pre-clinical Drug Screening and Discovery** Anne Dickinson, Ph.D., Emeritia Professor of Translational and Clinical Medicine, Newcastle University; CEO, Alcyomics
4:15-4:45 p.m.	**From AI Database Mining to the Identification of Therapeutic Target for Metabolic Disorders** Hong Wang, M.D., Ph.D., E.M.B.A., Director and Professor, Lewis Katz School of Medicine, Temple University

Clinical Development and Regulatory — Centennial Ballroom II

Session 1: New Trends in Clinical Trials

Session chair:	Dong-Jing (DJ) Fu, M.D., Ph.D., Senior Director of Clinical Development, Janssen R&D, LLC
3:15-3:45 p.m.	**Faster, More Inclusive, Patient-Friendly Clinical Research** Debra Weinstein, M.D., Vice President of Internal Medicine, Science 37
3:45-4:15 p.m.	**Medidata AI: Data Driven Approaches to Improving the Probability of Technical and Regulatory Success (PTRS)** John M Furgason, Ph.D., Director, Synthetic Control Arm Partnerships, Medidata Solutions

4:15-4:45 p.m.	**Quantitative Landscape Database Building and Modeling to Enhance Drug Development Probability of Success** Zhaoling Meng, Ph.D., Global Head of Clinical Modeling & Evidence Integration, Data and Data Sciences, R&D, Sanofi

Business — Centennial Ballroom I

Session 1: The Guide to Succeed in Business Development Despite IRA, Drying Capital, and Furious US/China Competition

Session chair:	Leon "Jun" Tang, Ph.D., Founder/Advisor InScienceWeTrust Bioadvisory, BioSpark Group
3:15-4:00 p.m.	**The Current Trends of the Global BD Trends in Therapeutics, with a Focus on the US/China Deal-making, and More** Leon "Jun" Tang, Ph.D., Founder/Advisor InScienceWeTrust Bioadvisory, BioSpark Group **The Legal Considerations When Conducting BD in the US, Especially for Foreign Companies** Peter Devlin, J.D., Partner, Jones Day **Recent Inspirative BD Cases Bridging across the Border** Pan Pan, Ph.D., Director, Business Development, Akeso, Inc.
4:00-4:45 p.m.	**Panel Discussion:** Leon "Jun" Tang, Ph.D., Founder/Advisor InScienceWeTrust Bioadvisory, BioSpark Group Tim Opler, Ph.D., Partner & Co-Founder, Torreya Peter Devlin, J.D., Partner, Jones Day Pan Pan, Ph.D., Director, Business Development, Akeso, Inc.

Promoting Patient Access Using Real-World Evidence — Frazer

Session 1: Health Economics and Outcomes Research

Session chair:	Lixia Yao, Ph.D., Principal, Polygon Health Analytics LLC; Adjunct Associate professor, Department of Health Services Administration and Policy, Temple University
3:15-3:45 p.m.	**Health Economic and Outcome Research for Product Development** Wei Zhou, M.D., Ph.D., Associate Vice President, Eli Lily and Company
3:45-4:15 p.m.	**Social Value of Medicines: A Critical Element in Value Assessment** Larry Liu, M.D., Ph.D., Executive Director, Merck & Co.
4:15-4:45 p.m.	**Role of HEOR Research in Driving Immunology Innovation and Commercialization** Joe Zhuo, Ph.D., Senior Director, Bristol Myers Squibb

Career Development Round Table Discussion		Devon

3:15-4:45 p.m. Marketing Yourself

- How to present your full ability
- How to present your ideas
- How to stand out among competitors in interview

Moderator:	Kevin He, M.B.A., Director of Business Operations, uBriGene
Panelist:	Alan Phan, CISSP, CISA, CIPT, CDPSE, Vice President - IT Audit, Chubb
	Edwin Empaynado, M.D., FACS, Physician, Advocare, LLC
	Yemisi Oluwatosin, Ph.D., Senior Medical Director, AstraZeneca
4:45-5:45 p.m.	**Reception & Networking**
6:00-9:00 p.m.	**Dinner (with tickets)** Grand Ballroom
Moderator	**Yufeng Li, Ph.D.,** Executive Director of Clinical Development, Qilu Pharma
6:00-6:15 p.m.	**President Speech**
	Haichen Yang, M.D., M.B.A., President of SAPA-GP 2022-23; Vice President, Clinical Research, Amicus Therapeutics
6:15-6:35 p.m.	**SAPA-GP Song Li Scholarship Ceremony**
	Song Li, Ph.D., Executive Chairman, Board of Directors, Frontage Laboratories
	Awardees: Jason Wang, Yale University
	Eric Han, Duke University

AGENDA Saturday, April 1st, 8:30 a.m.-6:30 p.m.

8:30-8:45 a.m. Check in

8:45-9:00 a.m. Welcome, President-elect Announcement & Speech — Grand Ballroom

Haichen Yang, M.D., M.B.A., President of SAPA-GP 2022-23; Vice President, Clinical Research, Amicus Therapeutics

Yang Yuan, Ph.D., President-Elect, SAPA-GP; Associate Director, Jazz Pharmaceuticals

President-Elect 2024

Plenary Session & Keynote Presentations — Grand Ballroom

Session chair:	Yang Yuan, Ph.D., President-Elect, SAPA-GP; Associate Director, Jazz Pharmaceuticals
9:00-9:45 a.m.	**Decentralized Clinical Trials and DTRA: What Are They Exactly and What Does the Future Look Like.** Amir Kalali, M.D., Founder & Co-Chair, Decentralized Trials and Research Alliance (DTRA)
9:45-10:30 a.m.	**Model Informed Drug Development – Approaches in Lifecycle Drug Development and Regulatory Decision Making** Joga Gobburu, Ph.D., M.B.A., Professor, University of Maryland, Baltimore, CEO, Pumas-AI, Inc, Founder & President, Vivpro Corp
10:30-10:50 a.m.	**Coffee Break**

10:50-12:20 p.m. Parallel Sessions

Drug Discovery and Development — Grand Ballroom

Session 2: Enabling Patient Centric Formulation Biologics Design by Pushing the Limit of Protein Concentration

Session chair:	Di Wu, Ph.D., Senior Scientist, Merck & Co.
10:50-11:20 a.m.	**Patient-centric Biologics Development: Accelerating Patient Impact through Innovation** Rubi Burlage, Ph.D., Associate Vice President, Sterile Product and Device Development, Merck & Co.
11:20-11:50 a.m.	**Developing Patient-centric High Concentration Biologics: Learnings from the Commercial Landscape** Hiten J. Gutka, Ph.D., Senior Principal Scientist, Bristol Myers Squibb
11:50-12:20 p.m.	**Different Models to Predict Human Bioavailability of Subcutaneously Administered Monoclonal Antibodies at Preclinical and Clinical Stages** Peng Zou, Ph.D., Director, Daiichi Sankyo Inc.

Clinical Development and Regulatory — Centennial Ballroom II

Session 2: Best Practice of Co-development of Drug and Companion Diagnostics (CDx)

Session chair:	Yufeng Li, Ph.D., Executive Director of Clinical Development, Qilu Pharma
10:50-11:20 a.m.	**Technical and Practical Aspects of an CDx Assay from Concept Design to Marketing Application** Nick Zhang, Board Chairman and CEO, MEDx Translational Medicine Co., Ltd
11:20-11:50 a.m.	**Current Regulatory Requirements of Biomarkers in Oncology Drug Development** Reena Philip, Ph.D., Associate Director for Biomarkers and Precision Oncology, Oncology Center of Excellence, FDA
11:50-12:20 p.m.	**Setting Companion Diagnostics Strategy for Precision Medicine in Oncology – Perspectives from Biotech** Frank F. Fan, M.D., M.B.A., Senior Vice President, AnHeart Therapeutics Inc

Business — Centennial Ballroom I

Session 2: Investment Winter – Alternative Strategy

Session chair:	Hangfei Fu, Ph.D., Equity Research Associate, TD Cowen
10:50-11:20 a.m.	**Alternative Financing Options for Biotech** Mark Tang, Ph.D., M.P.H., M.B.A., Managing Director, Good Health Capital
11:20-11:50 a.m.	**Lining up Business Plan Milestones with the Size of the Raise** Frederick "Rick" Jones, M.D., M.B.A., Partner, BioAdvance
11:50-12:20 p.m.	**From Idea to Product Launch: a Journey in Biotech Entrepreneurship and Fundraising** Bing Yao, Ph.D., CEO & Chairman of ArriVent Biopharma

Promoting Patient Access Using Real-World Evidence — Frazer

Session 2: Real World Data (RWD) and Real World Evidence (RWE)

Session chair:	Lixia Yao, Ph.D., Principal, Polygon Health Analytics LLC; Adjunct Associate professor, Department of Health Services Administration and Policy, Temple University
10:50-11:20 a.m.	**"What if" AI with Real-world Data from Prediction to Intervention Modeling to Fairness and Disparities** Jiang Bian, Ph.D., Professor & Chief Data Scientist, University of Florida
11:20-11:50 a.m.	**RWD/RWE: To Replicate Or Continue To Learn In The Real World?** John Cai, M.D., Ph.D., FAMIA, Executive Director, Outcome Research, Merck & Co.

11:50-12:20 p.m.	**Effectiveness of COVID-19 Vaccines in Children and Adolescents: Findings from Trial Emulation using an EHR-Based Cohort from the RECOVER Program** Yong Chen, Ph.D., Professor of Biostatistics, University of Pennsylvania

Career Development Round Table Discussion — **Devon**

10:50-12:20 p.m.	**Effective Communication in Workplace** • What cause the difficult communication? • Effective communication step by step action plan; • Interactive role play to deliver communication required skills/knowledge
Moderator:	David Cragin, Ph.D., DABT, Senior Director, Teva Pharmaceutical
Panelist:	Helen Sun, MHRM, SPHR, Head of Human Resource, Exegenesis Bio Co. John Wang, Ph.D., D.V.M., Associate Vice President, Eli Lilly

12:20 p.m.-1:30 p.m. Lunch Break and Networking

12:30 p.m.-1:25 p.m. Lunchtime Session

Pharmaron — **Haverford**

Host: Zhongwen (Adam) Luo, Ph.D., Senior Manager Regulatory Affair, WuXi Biologics

Decentralized Clinical Trials: Operational Strategies

Marion Stamp-Cole, M.B.A., Director, Pharmaron US Clinical Services

Morgan Stanley — **Paoli**

Host: Holly Meng, M.B.A., President/CEO, American Center for Asian Student (ACAS)

Managing Your Wealth While Helping You Achieve Your Goals

Serina Shi, CFA,CAIA, Financial Advisor, Morgan Stanley

MagStone Law, LLP — **Malvern**

Host: May Huang, CPA, Audit Partner, WWC, P.C.

From Here to Series A: a Legal Roadmap for Biomedical Startups

Enshan Hong, J.D., Partner, MagStone Law, LLP

Yue (Mark) Li, J.D., Partner, MagStone Law, LLP

GenScript Probio — **Frazer**

Host: Yutong Wu, M.S Student, Biotechnology, University of Pennsylvania

Robust and Rapid Antibody Discovery Platform in GenScirpt Probio

Lan Tang, Ph.D., Director, Business Development, GenScript Probio USA, Inc.

1:30-2:30 p.m. Parallel Sessions

Drug Discovery and Development — Grand Ballroom

Session 3: New Platform to Support Drug Discovery

Session chair:	Tao Niu, Ph.D., Associate Director, Clinical & Quantitative Pharmacology, Vertex Pharmaceuticals
1:30-2:00 p.m.	**Characterizing ADME Properties of Oligonucleotide Therapeutics** Wenying Jian, Ph.D., Director, Janssen Research & Development, J&J
2:00-2:30 p.m.	**Large-scale Characterization of Drug Candidates Against Transmembrane Receptors using HT-SPR** Eric Li, Ph,D., Associate Director, Application Development, ACROBiosystems
2:30-3:00 p.m.	**Harnessing the Power of the Human Memory B Cell** Matthew Robinson, Ph.D., Chief Technology Officer, Immunome

Clinical Development and Regulatory — Centennial Ballroom II

Session 3: Model Informed Drug Development (MIDD) - Approaches in Lifecycle Drug Development and Regulatory Decision Making

Session chair:	Yali Liang, M.D., M.S., M.P.H., Global Clinical Pharmacology & Pharmacometrics, Jazz pharmaceuticals
1:30-2:00 p.m.	**Model Informed Drug Development in Oncology: Clinical Pharmacology Perspectives** Suzette Girgis, Ph.D, Vice President, Head of Global Clinical Pharmacology & Pharmacometrics, Jazz pharmaceuticals
2:00-2:30 p.m.	**Physiologically Based Pharmacokinetic (PBPK) in Life Cycle Management and Regulatory Submissions** Weifeng Tang, M.D., Ph.D., Executive Director, Head of Vaccine and Immune, Neuroscience, Clinical Pharmacology & Pharmacometrics, AstraZeneca
2:30-3:00 p.m.	**Quantitative Systems Pharmacology (QSP) to Improve Hypothesis Generation in Pharmaceutical Drug Discovery and Development** Tarek Leil, Ph.D., Executive Director, Daiichi Sankyo, Inc

Business — Centennial Ballroom I

Session 3: Product Launch and Commercialization

Session chairs:	Shuang "Steve" Wu, Ph.D., M.S., Engagement Manager, Ambit Inc.
1:30-2:00 p.m.	**Commercializing Rare Disease Treatments: Key Challenges and How Ambit is Helping Companies Transform their Approach with Data and Analytics** Rob Sederman, M.B.A., Co-founder & CEO, Ambit Inc
2:00-2:30 p.m.	**Key Considerations and Strategies for Commercializing Cell Therapies in China** Richard (Liqun) Wang, Ph.D., M.B.A., Founder, Chairman and CEO, Neukio Biotherapeutics

2:30-3:00 p.m.	**Market Access – What, Why, When, and How** Kendig Bergstresser, Founding Partner, Integrity Biostrategies

Biopharma Compensation and Labor Law New Trends	Frazer
Session chair:	Helen Sun, MJRM, SPHR, Head of human resource, Exegenesis Bio Co.
1:45-2:15 p.m.	**Latest Update in Labor Law and Employee Rights** Richard Liu, Managing Counsel, Innovative Legal Services, P.C
2:15-2:45 p.m.	**The IPO Process and Employee Stock Options** Winston Kung, COO and CFO, PMV Pharmaceuticals, inc.
2:45-3:10 p.m.	**Q&A**

Career Development Roundtable	**Devon**
1:30-3:00 p.m.	**Transferrable Skill** • What skills could benefit you in any company/function • How to build transferable skills during your daily activities
Moderator:	Dennis Gross, Ph.D., Chief Executive Officer, Pennsylvania Drug Discovery Institute
Panelist:	Chad E. Beyer, M.B.A., CEO, Kures and Entrepreneur in Residence, Lafayette College
3:00-3:20 p.m.	**Coffee Break**

3:20-4:50 p.m. Parallel Sessions

Drug Discovery and Development	Grand Ballroom
Session 4: Discovery of Drug Targets with Novel Mechanisms	
Session chair:	Jun He, Ph.D., Assistant Professor at Department of Pathology and Genomic Medicine, Thomas Jefferson University
3:20-3:50 p.m.	**The Role of PRMT5 in Vascular Remodeling** Jianxin Sun, Ph.D., Professor of Medicine; Associate Director, Center of Translational Medicine, Thomas Jefferson University
3:50-4:20 p.m.	**AUTS2 and Neuronal Differentiation: Modeling and Mechanistic Characterization of Neurodevelopmental Disorders *in Vitro*** Zhonghua Gao, Ph.D., Associate Professor, Department of Biochemistry and Molecular Biology, College of Medicine, Penn State University
4:20-4:50 p.m.	**Target and Modality Selection For Treating CNS Diseases** Jason Uslaner, Ph.D., Vice President, Head of Discovery Neuroscience, Merck & Co

Clinical Development and Regulatory — Centennial Ballroom II

Session 4: Data Science in Accelerating Clinical Development

Session chair:	Qingqin Li, Ph.D., Senior Director, Data Science, Janssen Research & Development, LLC
3:20-3:45 p.m.	**Qualification Journey of Digital Biomarkers as Primary Endpoint** Srinivasan Vairavan, Ph.D., Director of Data Science and Digital Health, Janssen R&D, JNJ
3:45-4:10 p.m.	**Opportunities and Challenges of Applying ML and AI for Precision Oncology** Han Chang, Ph.D., Senior Director, Late-stage oncology, Informatics & Predictive Sciences, Bristol Myers Squibb
4:10-4:35 p.m.	**Data-driven RSV Disease Forecasting to Facilitate Large Clinical Trial Operation Excellence** Jennings Xu, Senior Director, Janssen R&D data Science & Digital Health, Janssen R&D, JNJ Xinggang Liu, M.D., Ph.D., Director, Janssen R&D, JNJ
4:35-5:00 p.m.	**Digital Endpoints That Matter to Patients** Pip Griffiths, Ph.D., Digital Medicine Society (DiMe)

Diversity & Inclusion — Centennial Ballroom I

Diversity, Equity and Inclusion: Awareness, Advocate and Action!

Session Chairs:	Kevin He, M.B.A., Director of Business Operations, uBriGene
3:20-4:50 p.m.	**Panel Discussion** Subarna Malakar, M.B.A., Head of Diversity, Equity and Inclusion, North America and Global Specialty Care, Sanofi Bridgett Battles, DEI Expert and Executive Presence Strategist, The Bridgett Battles Experience Elvie Gee, Executive Director, Global Inclusion & Diversity, Bristol Myers Squibb

Career Development Roundtable — Devon

3:20-4:50 p.m. **The Pharmaceutical Industry: What You Need to Know**

- Skillsets Needed in Big Pharm vs Medium/Small Size Biotech vs CRO
- Knowing what are different companies needs, choose the one fit your interests and comfortable working style
- Dos and donots in different kinds of companies

Moderator: Evelyn Guo, M.D., M.B.A., Medical Director, Astrazeneca

Panelist: Jay King, MD Ph.D., PMP, Director, Global Patient Safety, AstraZeneca

Michael Song, M.D., M.S., Executive Medical Director, Takeda Pharmaceutical Company

Expert Insights – Technical, Legal and More		Frazer
Session chair:	Jin Wen, Ph.D, Senior Scientist, Analytical Development, CMC, Spark Therapeutics	
3:20-3:50 p.m.	**The Biomarker Oriented Preclinical Study in the Era of Cell & Gene Therapy** Jing Deng, Ph.D., Vice President of Pharmacology, PD & Biology, Shanghai Medicilon Inc.	
3:50-4:20 p.m.	**Legal Considerations in Negotiating Preclinical and Clinical Agreements** Bin Hu Karg, J.D., Partner, Corporate & Technology Transactions, VCL Law LLP	

5:00-5:20 p.m.	Closing Remarks & Volunteer Awards	Grand Ballroom

Volunteer awards

Haichen Yang, M.D., M.B.A., President of SAPA-GP 2022-23; Vice President, Clinical Research, Amicus Therapeutics

Closing remarks

Yang Yuan, Ph.D., President-Elect, SAPA-GP; Associate Director, Jazz Pharmaceuticals

5:30-6:30 p.m. Reception & Networking

SAPA-GP Leadership

Haichen Yang, President (2022-2023)
Yang Yuan, President-Elect (2023-2024)

Annual Conference Leadership Team

Yufeng Li	Xinjun Zhang	Evelyn Guo

Program Track and Session Lead

David Cragin	Dongjing Fu	Hangfei Fu	Dennis Gross
Evelyn Guo	Kevin He	Jun He	Qingqin Li
Yufeng Li	Yali Liang	Bill Lu	Tao Niu
Penny Pan	Helen Sun	Leon Tang	Di Wu
Steve Wu	Lixia Yao	Xinjun Zhang	Yingying Zhou

Organizing Committee – Operational Leads

Sheng Hu	Hui Wang	Qi Wang	Sherry Wang
Di Wu	Saisi Xue	Ronghui Zhou	

Volunteers

Namila	Li Chen	Jiangchao Chen	Selina Chen
Qimin Chao	Zhiyi Cui	Shihao (Iris) Fang	Jinpeng Gao
Yifan Gong	Pengbo Guo	Dian He	Fan Huang
Shuo Huang	Coco Li	Siven Li	Yanchun Li
Lishan Liu	Minmin Liu	Xiaonan Liu	Jialie Luo
Tianying Jiang	Dongjun Peng	Zhen Qiao	Melinda Shen
Ruyu Shi	Prem Sreenivasan	Ian Sun	Xiaowei Sun
Jane Wang	Jiong Wang	Ruixi Wang	Sophia Wang
Mia Wu	Yutong Wu	Liping Xing	Jiahao Xu
Wenyu (Candice) Yan	Linxuan Yan	Yuan Yuan	Jie Zhao
Yunyun Zhou	Daniel Zhu		

SPEAKERS

Bridgett Battles

Director for Community Engagement and Supplier Diversity
Thomas Jefferson University and Jefferson Health

Bridgett is the Director for Community Engagement and Supplier Diversity at Thomas Jefferson University and Jefferson Health, she plays a key role in building Jefferson's relationships with community organizations and partners. In her role, Bridgett collaborates and cultivates meaningful relationships that impact and improve the lives of the diverse communities Jefferson serves through engagement in workforce readiness, celebrating small businesses and acting as a resource for health and welfare.
In collaboration with Jefferson's Supply Chain Department, Bridgett launched Supply Chain Connect to offer diverse potential suppliers the opportunity to pitch their business virtually, and get help in preparing their presentations. Jefferson's Supplier Diversity program is designed to connect more minority, women, veteran, persons with disabilities, and LGBT-owned small businesses to opportunities at Jefferson.

Kendig Bergstresser

Founding Partner
Integrity Biostrategies

Kendig Bergstresser has over 20 years of experience in Market Access for the bio-pharma industry in a variety of roles, from customer facing to strategy and headquarters based leadership. He currently helps bio-pharma companies with strategy, problem solving, tactics, and execution related to different aspects of market access. Kendig is also a soon to be published children's book author where he seeks to inspire the next generation.

Chad E. Beyer, Ph.D., M.B.A.

Chief Executive Officer
Kures

Dr. Beyer is a professional research scientist with more than 16 years of experience in drug discovery and the business development of medications designed to treat a variety of CNS and neurological disorders. For more than a decade, Dr. Beyer worked in the Discovery Neuroscience group at Wyeth Pharmaceuticals holding positions with increasing responsibility including serving as the Head of Neurochemistry and leading the Psychiatry Task Force. During his career, Dr. Beyer successfully managed several drug development teams, contributed to the submission of more than 30 INDs and provided supporting data for the commercialization and life-cycle management of 2 commercial products. Dr. Beyer's research career began at the NIH and he subsequently received a BS degree in psychology from Allegheny College, a PhD in pharmacology from LSU Medical Center and an MBA from the Rutgers Business School. Notably, Chad has authored more than 70 manuscripts, 3 patents, and is the co-editor of a psychiatry review book.



Jiang Bian, Ph.D.

Professor of Biomedical Informatics and Chief Data Scientist
University of Florida

Dr. Bian is Professor of Biomedical Informatics at the University of Florida (UF) and the Chief Data Scientist of the UF Health system. He also serves as the Director of Cancer Informatics Shared Resource (CISR) for the UF Health Cancer Center, Associate Director of the Biomedical Informatics Program for the UF Clinical and Translational Science Institute (CTSI), and the Chief Data Scientist for the OneFlorida+ Clinical Research Consortium. He have a diverse yet strong multi-disciplinary background in data integration, semantic web, machine learning, natural language processing, social media analysis, network science, data privacy, and software engineering. Nevertheless, his research serve an overarching theme: data science with heterogeneous data, information and knowledge resources, which can be divided into: (1) data-driven medicine—applications of informatics techniques, including machine learning methods in medicine on solving big data problems; (2) mining the Internet, including the social web, to provide insights into health-related behavior and health outcomes of various populations and finding ways to develop interventions that promote public and consumer health; and (3) development of novel informatics methods, tools and systems to support clinical and clinical research activities such as tools for data integration, clinical trial generalizability assessment, and cohort discovery.

Rubi Burlage, Ph.D.

Associate Vice President, Sterile Product and Device Development
Merck & Co.

Rubi Burlage, Ph.D. is Associate Vice President, Sterile Product and Device Development at Merck & Co., Inc. leading a group responsible for drug product and device development of Merck's sterile therapeutics and vaccine franchise. During her 17-year career, Rubi has impacted development of numerous products across disease areas and drug modalities having contributed to the successful development and launch of oral, sterile, implant, inhaled, and vaccine products. Previously, Dr. Burlage served as Executive Director of Sterile Drug

Product Commercialization within Merck's manufacturing division leading late-stage commercialization of Merck's parenteral products, including partnering on commercial process validation. Earlier, Dr. Burlage was Director of Oral Formulation Sciences at Merck, where she led the development of oral products and manufacturing technologies, primarily focusing on infectious and cardiovascular disease areas. Rubi's tenure at Merck has also included leadership roles in specialty product development, biopharmaceutics, and associated lifecycle management strategies advancing products from first-in-human to commercialization. Rubi's interests include understanding biopharmaceutical and mechanistic principles influencing dosage form design, studying factors germane to successful product and process scale up, and developing risk-weighted strategies for drug product commercialization. She is a co-author on several publications and co-inventor on 3 patents. Rubi is a strong advocate for STEM careers and actively lectures on industrial drug development at university graduate programs. Dr. Burlage also strongly believes in mentoring women, men, and minorities in leadership roles and the sciences, and has mentored many interns, co-ops, and early career colleagues. Dr. Burlage's efforts in advancing industrial pharmaceutics earned her the University of Iowa Genesis Alumni Award in recognition for her contributions to the field. Rubi earned a B.S. from India and Ph.D. from The University of Iowa. Dr. Burlage is a member of the American Association of Pharmaceutical Scientists (AAPS) and previously served as chair of the Drug Product Leadership Group for the International Consortium for Innovation & Quality in Pharmaceutical Development (IQ).

John Cai, M.D., Ph.D., FAMIA

Executive Director, Outcomes Research
Merck & Co.

John Cai, M.D., Ph.D., FAMIA, is Executive Director, Real-world Data Analytics and Innovation, in the Merck Center for Observational and Real-World Evidence (CORE). He is leading a team of data scientists and outcomes researchers to generate real-world evidence and insights through innovative and advanced analytics. John has more than 20 years of experience in biomedical and clinical research across academic, biotech, and pharmaceutical settings. John received his medical training from China Medical University and his Medical Informatics training from Harvard Medical School. Pursuing a passion for both medicine and computing, John has co-authored peer-reviewed publications in the areas of medical informatics, machine learning, clinical trials, and cancer genomics. John is a Fellow of the American Medical Informatics Association (AMIA) and serves in the AMIA Industry Advisory Council.

Han Chang, Ph.D.

Senior Director, Late-Stage Oncology, Informatics & Predictive Sciences
Bristol Myers Squibb Company

With over 20 years in the pharmaceutical industry, Han is a seasoned leader in applying advanced analytic methods for drug discovery and clinical development across multiple therapeutic areas. He currently leads a team of analysts using bioinformatics, statistics, and AI to advance BMS' oncology R&D pipeline.

Yong Chen, Ph.D.

Professor of Biostatistics
University of Pennsylvania

Dr. Yong Chen is a tenured Professor of Biostatistics at the Department of Biostatistics, Epidemiology, and Informatics at the University of Pennsylvania (Penn). He is an elected fellow of the American Statistical Association, the American Medical Informatics Association, Elected Member of the International Statistical Institute, and Elected Member of the Society for Research Synthesis Methodology.
Dr. Chen's research has been focusing on statistical and informatics methods for evidence generation using real-world data (RWD), specially on discoveries using multi-modal data and multi-site data. He has published over 170 peer-reviewed papers. In 2021, Dr. Chen was recently awarded by the Observational Health Data Sciences and Informatics (OHDSI) Titan Award for Methodological Research on his contributions to developing effective and efficient privacy-preserving distributed algorithms for data integration.
During pandemic, Dr. Chen is serving as Director of Biostatistics Core for PedPASC of the RECOVER COVID initiative which a national multi-center RWD-based study on Post-Acute Sequelae of SARS CoV-2 infection (PASC), involving more than 13 million patients across more than 10 health systems. Dr. Chen's research has been continuously supported by NIH, AHRQ and PCORI. He is currently the PI of six research awards from NIH and PCORI on real-world data, evidence synthesis, knowledge discovery, and drug repositioning.

Jing Deng, Ph.D.

Vice President of Pharmacology, PD & Biology
Shanghai Medicilon Inc.

Postdoctoral fellow of Harvard Medical School, doctor of Pharmacology and Therapeutics Department of McGill University, Canada, member of American Precision Medicine, member of American Society of Hematology, member of

American Cancer Society, member of North American Chinese Medical Association, leading talents in mass entrepreneurship and innovation in Jiangsu Province, leading talents in Suzhou Industrial Park, high-level talents in Jinji Lake, core members of Gusu (Suzhou) major innovation team and Jiangsu mass entrepreneurship and innovation team. In the past 22 years, Dr. Deng Jing has been deeply involved in the field of innovative drug research and development. Dr. Deng Jing has been deeply involved in international academic research in molecular biology/molecular pharmacology, functional genomics, proteomics, the creation of a platform for precise cancer treatment and diagnosis technology, and the research and development of internationally innovative anti-cancer drugs and biomarkers for clinical trials, It has also achieved remarkable innovative research and transformation achievements in the international pharmaceutical industry: it has participated in the whole process (clinical phase I and II) of the successful joint research and development of the world's first BCL-2 target new inhibitor Venetoclax (ABT-199) by Dana Farber Cancer Research Institute of Harvard University and AbbVie of the United States; For the first time in the world, BTK kinase inhibitors (Ibrutinib and Acalabrutinib) sensitized BCL-2 inhibitors (Venetoclax) were found at the level of molecular medicine at the clinical research stage. Before the academic publication, the research conclusion directly boosted the acquisition of BTK inhibitors for $21 billion, and thus became the "golden partner" of CLL treatment portfolio for chronic lymphoblastic leukemia; Create a dynamic BH3 analysis (DBP) platform for clinical medication guidance of cancer precise treatment; In recent years, more than 10 leading research topics have been selected into the World Cancer Research Conference; She has published many heavyweight papers at home and abroad.

Peter Devlin, J.D.

Partner
Jones Day

For over a decade, Peter Devlin has advised clients in connection with transformative financing transactions and day-to-day disclosure and corporate governance matters.
Peter advises companies and financial institutions across a wide range of public and private securities offerings, including initial public offerings and other equity offerings (both primary and secondary); investment-grade, convertible, and high yield debt offerings; and exchange offers, tender offers, and consent solicitations. He has significant experience advising domestic and international clients on securities laws, corporate governance matters, SEC reporting requirements, and stock exchange rules and regulations. Peter often counsels emerging companies on the legal and practical aspects of the public offering process in the United States.
Peter has worked with many types of issuers, ranging from emerging companies to multinational corporations, on transactions across many different industries, including agricultural technology, biotechnology, financial technology, financial services, insurance, transportation, shipping, consumer products, telecommunications, and education.
Peter is an advisory board member of the School of Science at Manhattan College.

Anne Dickinson, Ph.D

Professor of Translation and Clinical Medicine
Newcastle University;
CEO
Alcyomics

Anne Dickinson (Emeritia Professor of Translational and Clinical Medicine at Newcastle University), where she used human skin based in vitro assays for predicting graft versus host disease (GvHD). Her research work that has been extensively published in over 100 peer-reviewed journals. Anne was also a Health Professional Clinical Scientist and was the Director of Newcastle Cellular Therapy Facility and has experience in the regulatory framework involved in Good Manufacturing Practice (GMP) for the development of Advanced Therapy Medicinal Products (ATMPs). Anne's research led to the founding of Alcyomics in 2007, where the technology was modified for predicting adverse immune skin and systemic responses to compounds including chemicals, cosmetics, pharmaceuticals and cellular therapies and patents have been granted within Europe and the USA. Anne has over 12 years' experience in developing commercial contracts for some of the top ten pharma companies as clients and a wealth of experience in obtaining successful commercial and research funding at the national and international level. She has coordinated international EU projects for 20 years.

Edwin Empaynado, M.D., F.A.C.S.

Physician
Advocare LLC

Edwin Empaynado is Board Certified in General Surgery, Board Certified in Colon and Rectal Surgery, and a Fellow of the American College of Surgeons. He is licensed by the New Jersey Board of Medical Examiners and has been in private practice in the South Jersey area since 2006. Edwin has previously been recognized by his peers through SJ Magazine, New Jersey Monthly, and Healthy Living Magazine with "Top Doc" honors in his specialty. Dr. Empaynado is a managing partner in Advocare Colon and Rectal Surgical Specialists, a subdivision of Advocare, LLC, where he is the Care Center Vice President of two office locations in South Jersey and an active member of various committees.
Edwin received his Bachelor of Science degree in Biology from The Pennsylvania State University Eberly College of Science. He earned a Medical Doctorate degree from UMDNJ – New Jersey Medical School, Newark, NJ and completed a General Surgery internship/residency program at UMDNJ – Robert Wood Johnson Medical School, New Brunswick, NJ. He pursued additional Fellowship training in the subspecialty of

Colon and Rectal Surgery as a Fellow at Lehigh Valley Health Network, Allentown, PA.

Frank F. Fan, M.D., MBA

Senior Vice President
AnHeart Therapeutics Inc

Dr. Fan has more than 20 years of working experience with several leading global R&D based biopharmaceutical companies and focused on medical science and clinical development strategy. He was the head of clinical development strategy and scientific services at IQVIA in Asia, and prior to that he had been working with Pfizer, and Novartis on several clinical development programs in oncology, hematology, and immunology therapeutic areas. Dr. Fan obtained his MD degree in China and MBA in the United Kingdom.



John M Furgason, Ph.D.

Director, Synthetic Control Arm Partnerships
Medidata Solutions

An experienced data collaboration manager with a diverse background, Mike has managed scientific research portfolios across the academic and industry landscape. A prolific "dot connector", he has taken his passion for building and realizing the value of multimodal data assets into his current role at Medidata, where he works alongside biopharma veterans, clinicians, data scientists, and many others to leverage Medidata's historical clinical trial (HCT) database to help address current challenges surrounding the use of external data in the regulatory setting.



Zhonghua Gao, Ph.D.

Associate Professor
Penn State University College of Medicine

My primary research goal is to elucidate the molecular mechanism through which Polycomb repressive complexes (PRC) control cell fate transition. After graduating from Weill Cornell with a Ph.D., I joined Dr. Danny Reinberg's laboratory at New York University in 2009 as a postdoctoral fellow and received rigorous training in biochemistry and epigenetics. Through a combination of biochemical and genomic approaches, I identified a family of mammalian PRC complexes targeting distinct functional groups of genes (Gao et al., Mol Cell 2012). This study serves as a foundation for my current and future research program. Also, it significantly impacts the field, as evidenced by the ~800 citations it has generated to date. As I continued investigating the PRC1 complexes, I uncovered the surprising and highly intriguing presence of Autism Susceptibility Candidate 2 (AUTS2) in a novel class of PRC1 complexes, referred to as PRC1-AUTS2. In stark contrast to the traditional repressive role of PRC1 complexes, I demonstrated the PRC1-AUTS2 complex activates transcription and regulates neurodevelopment using a mouse model (Gao et al., Nature 2014). In 2015 I established my lab at the Department of Biochemistry and Molecular Biology, Penn State University College of Medicine, and was promoted to Associate Professor with tenure in 2022. Since my appointment at Penn State, I have continued investigating how epigenetic mechanisms regulate cell identity and how the deregulation of these mechanisms leads to diseases. This line of studies led to the discovery of novel binding partners and pathways that are critical to regulating the cell fate transition from embryonic stem cells (ESC) to neuronal progenitors (NPC) (Wang et al., Stem Cell Res 2018; Geng et al., Stem Cell Rev Rep. 2022). In addition, in a collaborative effort, we have identified novel functions for PRCs to regulate HSPC self-renewal and differentiation (Chen et al., Nature Comm 2019).

Elvie Gee

Executive Director, Global Inclusion & Diversity
Bristol Myers Squibb

Elvie Gee (pronouns she/her/hers) is the Executive Director, Global Inclusion & Diversity (GI&D) at Bristol Myers Squibb (BMS). She provides strategic I&D thought leadership and leads the Center of Excellence enabling the operationalization of BMS' Inclusion & Diversity strategy across the globe. Under Elvie's leadership, her GI&D Center of Excellence team is focused on developing and delivering bold and innovative GI&D solutions, resources and services across BMS, as well as gleaning insights from talent analytics and employee sentiment to inform the activation plan for the I&D strategy. She also has oversight for the People & Business Resource Groups (PBRGs) across BMS globally with over 14,500 members. Elvie joined Bristol Myers Squibb with over a decade of experience with global Fortune 100 companies and has worked in the United States and Canada. She has developed global enterprise-wide strategies in the areas of diversity, equity and inclusion, talent management and change leadership.Elvie is passionate about advocating for people with disabilities, being a caregiver of a child on the autism spectrum, which has led to the work she leads today. Originally from Montreal, Quebec, Canada, Elvie is currently based in Princeton, New Jersey.

Suzette Girgis, Ph.D.

Vice President, Head of Global Clinical Pharmacology & Pharmacometrics
Jazz Pharmaceuticals

Suzette is a passionate, strategic drug developer with over 20 years of experience in small molecules, biologics, and cell therapy, ranging from discovery to commercialization, with a

particular emphasis on oncology. Suzette joined Jazz Pharmaceuticals in October 2022 as the VP and Head of Global Clinical Pharmacology and Pharmacometrics. Suzette is recognized as an expert in dose selection for First in Human and Proof of Concept studies. Over the years, she has made significant contributions to the development of several marketed compounds as the clinical pharmacology leader, including belatacept (Nulojix®), bortezomib (Velcade®), decitabine (Dacogen®), and teclistamab (Tecvayli®). Suzette has a strong commitment to mentoring and talent development and is a strong advocate of rotation programs.

Suzette earned her BPharm Degree from Cairo University and her MS and PhD in Pharmaceutical Sciences, specializing in PK/PD modeling, from the University of Rhode Island. After completing her studies, Suzette began her career as a Postdoctoral Research Fellow in Clinical Pharmacokinetics at Johnson & Johnson. She later joined the Drug Metabolism and Pharmacokinetics Department of Schering-Plough (currently Merck), where she worked on early development compounds in neuroscience, cardiovascular, and virology. Subsequently, Suzette joined the clinical pharmacology department at Bristol Myers Squibb, where she worked on oncology and immunology compounds and later oversaw the clinical pharmacology activities for the Immunology Therapeutic Area. She has also directed many clinical pharmacology studies in oncology, immunology, neuroscience, cardiovascular, and metabolic diseases. In 2008, Suzette rejoined Johnson & Johnson as a director in Global Clinical Pharmacology, where she took on increasing roles and responsibilities, including the US Head of Scientific and Technical Operations in the Clinical Pharmacology Department. Prior to joining Jazz, Suzette served as the Clinical Pharmacology Head of Hematologic Malignancies at Janssen, where she developed multiple immuno-oncology compounds (including bispecifics, trispecifics, and CAR-T), implemented model-informed drug development principles, and oversaw the clinical pharmacology strategy of heme pipeline.

Suzette has published many manuscripts in prestigious journals including the New England Journal of Medicine and Lancet. She has presented at many scientific conferences such as ASH, ASCO, EHA, ESH, IMW, ACoP, and AAPS. When not working, Suzette enjoys spending time with her family, including her husband Ihab, two daughters Abigail and Sarah, and a ragdoll cat named Luna. She is also active in her local church, where she volunteers her time to serve the community. Suzette is based in NJ.

Joga Gobburu, Ph.D., M.B.A

Professor, School of Pharmacy and School of Medicine
University of Maryland, Baltimore

Dr. Gobburu is a Professor with the School of Pharmacy and the School of Medicine, University of Maryland, Baltimore, MD, USA. He held various positions at the US FDA between 1999 and 2011. Under his leadership, a Division of Pharmacometrics was formed at the FDA and several policies were established. He is a world-recognized scientific leader in the area of quantitative disease models and their application to decisions. Dr. Gobburu is best known for transforming the field of Pharmacometrics across the world into a decision-supporting science. He also established a Pharmacometrics Fellowship program at the FDA. He received numerous FDA awards such as the Outstanding Achievement Award. He also received the Outstanding Leadership Award from the American Conference on Pharmacometrics (2008), the Tanabe's Young Investigator Award from the American College of Clinical Pharmacology (ACCP) (2008) and the Sheiner-Beal Pharmacometrics Award from the American Society of Clinical Pharmacology and Therapeutics in 2019. Dr. Gobburu is on the Editorial Boards of several journals and a Fellow of ACCP, AAPS and International Society of Pharmacometrics. He has published over 120 papers and book chapters.

Pip Griffiths, Ph.D.

Digital Medicine Society (DiMe)

Pip has a background in measurement science. She worked in the pharma industry as a consultant to help clients understand who their questionnaires worked, whether they were valid, reliable and able to detect change. She saw that this work was burgeoning in the digital medicine space and joined with DiMe to be able to further implement good measurement science strategy in the digital measurement field.

Hiten J. Gutka, Ph.D.

Senior Principal Scientist
Sterile Product Development
Bristol Myers Squibb

Hiten Gutka, Ph.D., works as a Senior Principal Scientist, Sterile Product Development at Bristol Myers Squibb. Prior to this role he was Senior Scientist Biologics Development at Celgene. He worked as Associate Director Formulation Development at Outlook Therapeutics Inc. (formerly Oncobiologics Inc.) where he developed a proprietary bevacizumab drug product (LYTENAVA) for intravitreal injection. He also worked on biosimilar drug product development at Oncobiologics Inc. He worked on formulation and stabilization of novel insulin analogues at Thermalin Diabetes LLC. He did a co-op at Medimmune LLC, in the Formulation Development group. Hiten holds PhD in Pharmacognosy (Pharmaceutical Biotechnology track) from University of Illinois at Chicago, College of Pharmacy. His graduate research work involved structural and functional characterization of fructose 1,6-bisphosphatase from pathogenic bacteria namely Mycobacterium tuberculosis and Francisella tularensis. Hiten worked at Biocon, USV and Reliance Biopharmaceuticals in India, on analytical and

pharmaceutical development of biosimilars. He holds a BS and MS Degree in Pharmaceutical Sciences from University of Mumbai, India. Hiten is a member of the American Association of Pharmaceutical Sciences (AAPS). He serves on the editorial board of Bioprocess International and the journal mAbs.

Danuta Herzyk, Ph.D.

Scientific Associate Vice President
Merck & Co.

Dr. Herzyk is Scientific Associate Vice President at Merck &Co. in the Department of Nonclinical Drug Safety. Prior to joining Merck, Dr. Herzyk was a Director of Immunologic Toxicology Laboratory in Nonclinical Safety Assessment at GlaxoSmithKline. In the current position at Merck, her role as the Therapeutic Area Leader in Oncology and Immunology is to provide guidance in the preclinical development and safety assessment of novel therapeutics, including chemical and biological drugs as well as vaccines. Dr. Herzyk has been involved in the development of approved medicines such as KEYTRUDA®, ILUMYATM and WELIREGTM. Dr. Herzyk is author or co-author of 60 peer-reviewed articles and co-editor of two books, "Immunotoxicology Strategies for Pharmaceutical Safety Assessment" and "Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics". She served on BioSafe Leadership Committee and had multiple roles in Immunotoxicology Specialty Section and BioTechnology Specialty Section of the Society of Toxicology.

Enshan Hong, J.D

Partner
MagStone Law, LLP

Enshan Hong has over 20 years of experience in almost all aspects of intellectual property law, with particular emphasis on the acquisition and protection of patent and trademark rights. He is also experienced in client counseling, transactional, and litigation matters. He has counseled clients on a variety of intellectual property matters with an emphasis on infringement and validity issues, freedom to operate opinions, and patentability evaluations. His transactional experience ranges from due diligence investigations to licensing arrangements, including drug discovery, research, manufacturing, and marketing agreements. His litigation experience includes disputes regarding patents and trademarks, in particular patent litigations related to Hatch Waxman Act. Enshan has served numerous domestic and international clients in the life science and medical device fields. Enshan graduated from the China University of Petroleum with a bachelor's degree in chemical engineering, the University of New Hampshire Franklin Pierce School of Law with a master's degree in intellectual property law, and Rutgers University School of Law with a Doctor of Law (JD) degree. Prior to joining MagStone Law, Enshan first practiced at a leading IP boutique firm in New York City for ten years and then at two general practice national firms for nine years in total.

Wenying Jian, Ph.D.

Director of Bioanalytical Discovery and Development Sciences
Janssen Research & Development, Johnson & Johnson

Dr. Wenying Jian is currently a Director of Bioanalytical Discovery and Development Sciences (BDDS) of Janssen Research & Development, Johnson & Johnson. She is leading a team that is responsible for bioanalytical support of preclinical and clinical studies for small molecule and oligonucleotide programs. She also serves as function representative for novel modalities such as LNP encapsulated mRNA vaccine. Dr. Jian has over 18 years of industrial experience with Bristol-Myers Squibb and then Johnson & Johnson. She has published over 60 journal papers and book chapters, and co-edited the book "Targeted biomarker quantitation by LC-MS" (Wiley, 2017) and "Sample preparation in LC-MS bioanalysis" (Wiley, 2019). She currently serves on the editorial board of Journal of Pharmacological and Toxicological Methods and the board of EAS. Dr. Jian received her B.S. in Pharmacy from Beijing Medical University, M.S. in Microbiology from Chinese Academy of Sciences, and Ph.D. in Pharmacology from University of Pennsylvania.

Frederick 'Rick' Jones, M.D., M.B.A.

Partner
BioAdvance

Frederick "Rick" Jones, M.D., M.B.A. is a Partner at BioAdvance, a Philadelphia-based early stage biotech venture capital firm. Dr. Jones has spent over 30 years in life science industries, serving as a physician, executive, consultant, director and investor. At BioAdvance he is responsible for investments in therapeutics and medical devices.
Previously Dr. Jones was a Director at Broadview Ventures, a Boston-based philanthropic venture fund focused on breakthrough technologies in cardiovascular disease. Prior to Broadview Dr. Jones served as CEO of Anchor Therapeutics, a venture-backed company, which was developing a platform based on peptide modulators of GPCRs. Prior to Anchor, Dr. Jones held executive positions with Devgen NV (Ghent, Belgium) and BioRexis (acquired by Pfizer). Dr. Jones began his industry career at Wyeth Pharmaceuticals, initially in Global Medical Affairs and subsequently in Global Business Development. Dr. Jones is a board-certified internal medicine physician who practiced in the US Navy, the Lahey Clinic (Burlington, MA) and at the University of Pennsylvania. He received his BA, MD and MBA degrees from the University of Pennsylvania.



Amir Kalali, M.D.

Founder and Co-Chair
Decentralized Trials and Research Alliance (DTRA)

Dr. Kalali is a physician scientist, recognized globally as a leading innovator at the intersection of life sciences and technology, and a convener of collaborative high impact forums. He is a board director of both private and publicly traded companies and advises companies in the life sciences and technology sectors, universities and investment groups. Dr. Kalali is the Co-Chair of the Decentralized Trials and Research Alliance (DTRA), Chairman and Chief Curator of the CNS Summit, a forum focused on the future of life sciences, and was the Founding Chairman, and sits on the Executive Committee of the International Society for CNS Drug Development (ISCDD), one of the first independent non-profits to bring together leaders in drug development to collaborate. He is Professor of Psychiatry at University of California San Diego, Editor of the journal Innovations in Clinical Neuroscience, and the Lead Editor of the book Essential CNS Drug Development., published by Cambridge University Press. He has authored over 250 peer-reviewed publications, and numerous book chapters. He has been involved in initiatives by the Institute of Medicine, as well as the NIH FAST and the NIH NCATS programs.

Bin Hu Karg, J.D.

Partner
VCL LAW LLP

Bin Hu Karg is a corporate and technology transactions attorney with over a decade of experience specializing in the life sciences industry. Bin's corporate practice focuses on representing life sciences, technology and growth business enterprises at all stages of development, guiding them from inception into fundraising and eventually exiting through IPOs or mergers and acquisitions. She acts as an outside general counsel to start-ups, and as they expand, continues to serve their increasingly sophisticated legal needs. Her areas of expertise include fundraisings, mergers and acquisitions, corporate governance, joint ventures, SEC compliance, public offerings and other corporate and securities law matters.

Bin's technology transactions practice focuses on advising pharmaceutical and biotech companies on technology, IP and commercial transactions throughout the entire process of drug development and commercialization. She has significant experience in negotiating technology licensing, co-development and commercialization, master service agreements with contract research organizations for pre-clinical and clinical studies, biologics development and manufacturing, collaborative and sponsored research, distribution arrangements, material transfer agreements, and nondisclosure agreements. Bin is also well recognized for her extensive experience in cross-border transactions. Having counseled foreign companies in conducting business in the U.S. as well as domestic buyers and investors in investments and acquisitions in Asia and Europe, she is well positioned to be a trusted advisor to her clients in carrying out their global strategies.

Bin graduated from Columbia Law School. She is admitted to practice law in New York and Texas. Her working languages are English and Chinese. She can also carry on basic conversations in German.

Jay King, M.D., Ph.D., P.M.P

Director, Global Patient Safety
AstraZeneca

Many years of clinical practice coupled with 25 years in the pharma/biotech industry with experience covering clinical development, regulatory and medical affairs, drug safety & pharmacovigilance in local & global capacities.

Winston Kung

Chief Operating Officer and Chief Financial Officer
PMV Pharmaceuticals, Inc.

Winston is currently the Chief Financial Officer and Chief Operating Officer at PMV Pharma. Prior to joining PMV Pharma, Mr. Kung was a Vice President of Business Development and Global Alliances at Celgene and Chief Business Officer at Celgene Cellular Therapeutics (CCT). While at Celgene, he led the strategic long-range plan formation, multiple transactions, equity investments, company integrations, and a team that managed Celgene's alliance portfolio of more than 100 collaborations. Prior to Celgene, Mr. Kung worked from 2007 to 2013 at Citigroup in its Global Healthcare Investment Banking group and Lehman Brothers (which was subsequently acquired by Barclays) in its Global Mergers and Acquisition Group. He worked on various transactions including public and private financings, mergers, acquisitions, spin-outs and other financial advisory engagements.

Virginia M.-Y. Lee, Ph.D.

Professor, Department of Pathology and Laboratory Medicine, Perelman School of Medicine
University of Pennsylvania

Dr. Virginia M.-Y. Lee studied music at the Royal Academy of Music in London (1962-1964) and received her PhD in Biochemistry from the University of California at San Francisco in 1973. She joined the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine in

1981 and rose to become Professor of Pathology & Laboratory Medicine in 1989. Dr. Lee identified tau, alpha-synuclein and TDP-43 as disease proteins that form unique inclusions in Alzheimer's, Parkinson's and frontotemporal degeneration/Lou Gehrig's disease, respectively, and has advanced understanding of their roles in these disorders. Dr. Lee's h-index is 146 and she is listed among the 10 most highly cited AD researchers from 1985-2008 and among the top 400 most highly influential biomedical researchers from 1996-2011. ISI has recognized Dr. Lee as an ISI Highly Cited Researcher and places her in the top 10 most highly cited neuroscientists from 1997 to 2007.

Tarek Leil, Ph.D.

Executive Director
Daiichi Sankyo, Inc.

Tarek Leil is currently the head of QSP, Advanced Pharmacometrics (PMx) and Specialty Medicines Clinical Pharmacology (SMCP) at Daiichi Sankyo (DS). These groups have the common objective of promoting and leveraging model informed drug discovery and development (MID3), albeit from slightly different points of view. The QSP group develops mathematical mechanistic disease models to integrate prior non-clinical and clinical knowledge to inform key decisions in discovery and early clinical development. The Advanced PMx and SMCP groups typically utilize more empirical model-based approaches to optimize clinical development in later clinical development.

Prior to joining DSI, Dr. Leil led a large modeling group at Bristol-Myers Squibb (BMS), including a QSP group of ~ 16 scientists. He also worked as a Clinical Pharmacologist at Pfizer, and as a Pharmacometrician at BMS. Over his ~ 25-year scientific career, he engaged with numerous stakeholders in industry, academia and regulatory agencies to increase the understanding of, and potential impact for MID3 and QSP. He has also been influential in engaging with regulators on the development of best practices and review strategies for QSP containing submission. During his career Tarek has published over thirty journal articles and been an invited conference speaker nearly thirty times.



Song Li, Ph.D.

Founder, Executive Chairman
Frontage Laboratories, Inc and
Frontage Holdings Corporation

Song Li, Ph.D., is the founder, Executive Chairman of Frontage Laboratories, Inc and Frontage Holdings Corporation. Dr. Li was born and raised in a village of Henan Province in the People's Republic of China. He received his B.S degree in Chemistry from Zhengzhou University and taught chemistry in the same university for 5 years. Dr. Li received his Ph.D. in Analytical Chemistry from McGill University in 1992. After two years of post-doctoral research at the Oncology Department, the Medical School of McGill University, Dr. Li moved to the United States, where he held management positions at Great Valley Pharmaceuticals and Wyeth.

In 2001, Dr. Li founded Frontage Laboratories in New Jersey. Today, Frontage Holdings Corp, together with its wholly owned subsidiaries including Frontage Laboratories, Inc., is a global Contract Research Organization (CRO) with more than 1800 employees. Frontage provides integrated, science-driven, product development services from drug discovery to late-phase clinical process to enable biopharmaceutical companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment, and early-phase clinical studies. Frontage has enabled many biotechnology companies and leading pharmaceutical companies of varying sizes to advance a myriad of new molecules through development and to successfully file global regulatory submissions. Dr. Li has been the recipient of numerous awards, including the 'Realizing the American Dream' award from the Welcoming Center for New Pennsylvanians, 'Outstanding 50 Asian Americans in Business' award from AABDC. Dr. Li won 2018 Healthcare CEO Award sponsored by PACT and 2018 EY Entrepreneur Award.

Yue (Mark) Li, J.D

Partner
MagStone Law, LLP

Yue (Mark) Li, a partner of MagStone Law, LLP, is a seasoned corporate and securities attorney with extensive experience in venture financing, mergers and acquisitions, and start-up representations. At MagStone, Mr. Li has advised a number of leading firms, including Bitmain, CertiK, Danhua Capital, EastRich, Haiyin Capital, Jingdong Digits, JD Capital, K2 Capital, SV Tech, SWC Global, Tripalink, and Tsinghua Asset Management. At MagStone, Mr. Li's biotech and life sciences clients include, among others, Aptitude Medical Systems, Denovo Biopharma, D2M Biotherapeutics, Endovastec, iRay Technology, Leveragen, MicroPort Navipot, Paragon Genomics, and Simcere Pharmaceutical.

Prior to founding MagStone Law's New York office, Mr. Li worked at the New York offices of Davis Polk & Wardwell LLP and DLA Piper LLP, where he worked on some of the highest-profile corporate transactions in the world and developed a broad-based, well-rounded skill set. Mr. Li received his undergraduate degree from Peking University and a juris doctor degree, magna cum laude, from the Georgetown University Law Center.

Eric Li, Ph.D.

Associate Director of Application Development
ACROBiosystems

Eric Li is the Associate Director of Application Development at ACROBiosystems. Before joining ACRO, Eric had worked at DuPont, SDIX, and Ethos Biosciences, playing various roles in R&D, tech transfer, manufacturing, and sales and marketing focusing on protein, antibody, and immunoassay development and applications. He graduated from the Chinese Academy of Sciences and had postdoc training at the University of Pennsylvania. Eric is responsible for leading R&D activities, driving innovation efforts to develop new products and technologies, and collaborating across multi-functional teams based on Innovation Lab in Delaware.

Larry Liu, M.D., Ph.D.

Executive Director
Merck & Co.

Dr. Larry Liu is a well-known expert in Outcomes Research, Epidemiology and Health Economics. He is currently Executive Director, Outcomes Research, Merck Center for Observational and Real-world Evidence (CORE). He was at Pfizer for 12 years as Senior Director, Outcomes and Evidence for CV/MET, Global Health and Value. Larry was responsible for managing/developing Health Economics and Outcomes Research strategies for cardiovascular and diabetic products. Before joining Pfizer, Larry worked for Wyeth as Director, Global Health Outcomes Assessment. He was responsible for developing and implementing global health outcomes strategy for vaccines and infectious diseases. Prior to that position Larry was at GlaxoSmithKline as a Senior Epidemiologist supporting diabetes-related products.
He also worked for New Jersey State Health Department and China CDC for five years each in the past. Larry has adjunct faculty position at the Weill Medical College of Cornell University. He has published more than 70 scientific articles in medical journals (including JAMA and Lancet). Larry received his Medical Degree from Anhui Medical University, China and PhD in Epidemiology from UCLA.

Richard Liu

Managing Counsel
Innovative Legal Services, P.C

As the managing counsel of ILS, Richard is one of the top trial and compliance lawyers in the medical and pharmaceutical industry. He is known for understanding the unique legal and business challenges that companies in these industries face and developing innovative strategies to help them achieve their objectives. When faced with complex situations, Richard can quickly identify key issues, minimize legal risks, and consistently obtain favorable outcomes for his clients. As a former member of two top-tier defense firms in the country, Richard regularly advises medical and pharmaceutical companies, startups, and their executives on a range of commercial, regulatory, and compliance matters. His practice focuses on defending clients in litigation, preventing litigation through innovative counseling, and helping clients navigate complex investigations. With respect to litigation, Richard specializes in claims involving intellectual property infringement, trade secrets misappropriation, white collar investigation, wrongful termination, wage and hour defense, and employment discrimination. As to compliance, Richard is an expert in issues such as data security, privacy, employment practices, and compensation/benefits. Richard regularly appears before federal and state courts on behalf of medical and pharmaceutical clients. His clients appreciate his deep understanding of the industry, as well as his scrupulous attention to detail and his relentless pursuit of excellence. As a distinguished member of the bar in multiple jurisdictions, Richard combines the experience of big law firms with the highly individualized and responsive capacity of a boutique firm. Richard advocates to win."

Xinggang Liu, M.D., Ph.D.

Director
Janssen Pharmaceuticals

Xinggang is a director from the JRD Data Sciences Portforlio Management, focusing on the ID&V therapeutic area. He received his PhD in Epidemiology from University of Maryland, Baltimore, with past research in genetic epidemiology, clinical trial management and advanced predictive modeling using real-world data.

Subarna Malakar, M.B.A.

Head of Diversity, Equity and Inclusion, North America and Global Specialty Care
Sanofi

Subarna Malakar is the Head of Diversity, Equity and Inclusion for Sanofi North America and Global Specialty Care. He is also a member of the North America H.R. Leadership team and the Global Diversity, Experience and Culture team.
He also serves as an Advisory Member of the U.S. and Canadian Executive Diversity, Equity and Inclusion Councils for Sanofi.
In his current role, Subarna builds the DE&I foundation and leads a comprehensive and measurable diversity, equity and inclusion strategy integrated with the overall business and talent strategies. He drives DE&I strategy and initiatives to embrace and leverage diversity within the organization, support Sanofi's

diverse patient and customer base and achieve the Company's global diversity, equity and inclusion vision.
Prior to Sanofi, Subarna was with FMC Corporation and Ahold Delhaize, where he was Global Diversity & Inclusion Officer and Vice President, Global Chief Diversity Officer. He has more than 25 years of professional experience with 17 years in diversity, equity & inclusion, corporate social responsibility, culture change management, organizational and talent development, and project management working for global companies including Thomson Reuters, Unilever, and Sodexo and have lived in Germany, Netherlands and Singapore.
Subarna holds an MBA from Temple University: Fox School of Business, a Bachelor of Science from the University of Maryland, and a Certificate in Leadership Academy from Harvard University. He also serves as a board chair for National Associations of Asian American Professionals – Philadelphia and a board member for Institute for Corporate Productivity (i4CP) Chief Diversity Officers Board.
Subarna is a U.S. Army veteran and currently lives in Pennsylvania with his wife and daughter.

Zhaoling Meng, Ph.D.

Head of Clinical Modeling & Evidence Integration, Data and Data Sciences, R&D
Sanofi

Dr. Zhaoling Meng is Associate Vice President, Global Head of Clinical Modeling and Evidence Integration in Data and Data Sciences, sanofi R&D. Zhaoling has 20+ years of experience in Pharma industry with drug development experiences from discovery/statistical genetics, nonclinical, Phase I to III, world-wide submissions and in-licensing/due diligence. She built and leads a global team to support and promote modeling & simulation (M&S) and quantitative decision making across drug development stages. She worked in various disease areas including oncology, inflammation & immunology, rare disease, diabetes, cardiovascular and infection diseases. Her research interests include development modeling and design decision via competitive landscape analysis, real world data use in informing clinical studies, clinical modeling and simulation to trial optimization, and AI/deep learning in clinical applications. Prior to sanofi, Dr. Meng also worked at Bill and Melinda Gates Medical Research Institute, Merck, Pfizer and GSK. Zhaoling holds a PhD in statistical genetics from North Carolina State University.

Yemisi Oluwatosin, Ph.D.

Senior Medical Director
AstraZeneca

Yemmie holds a Ph. D in Biochemistry and Molecular Biology from SUNY Upstate Medical University in Syracuse, NY, and an MBA from the University of Delaware.
Yemmie completed post-doctoral fellowship at the University of Pennsylvania where she studied the molecular pathways involved in breast cancer metastasis.
Yemmie joined AstraZeneca in 1999 as a Research Scientist, working on identification of new drug targets for neurological and psychiatric disorders. One of her many successes in the laboratory was leading a drug discovery project that progressed to early stage clinical trials. Later, she worked in the field as a Medical Science Liaison before returning to headquarters. In Promotional Regulatory Affairs, she held different roles with increasing responsibilities and across multiple therapeutic areas covering nearly 20 branded products. She returned to Medical Affairs as one of the earliest members of AstraZeneca US renal therapy area.
Yemmie is passionate about mentoring and education, especially STEM education and frequently serves as a volunteer on STEM-related committees and initiatives. Yemmie was recently appointed Delaware State Science Ambassador as part of the nationwide.

Tim Opler, Ph.D.

Partner & Co-Founder.
Torreya

Tim has 24 years' experience leading strategic and financing transactions across multiple sectors. For nearly 20 years, he has focused exclusively on life sciences advisory; he has completed more than 150 financing, licensing, and M&A transactions across the industry with a total value of over $100 billion. Highlights include running the largest share buyback in history for Pfizer, leading a $3.9 billion convertible bond exchange for Amgen, working on Chiron's $5.1 billion sale to Novartis, and managing Genentech's inaugural $2 billion bond issue.

Pan Pan, Ph.D.

Director of Business Development,
Akeso, Inc.

Dr. Pan Pan has over 10 years of experience in Strategic Planning, Business Development & Licensing, Alliance Management, and Drug Development. He has been focused on collaborative development, strategic partnering and licensing transactions for innovative biological drugs in oncology and immunology. Dr. Pan has served as the group lead of Business Development at Akeso Biopharam, KLUS Pharma, and several other small to mid-cap biotech companies, with a track record of executing partnerships with record-high values, including a $1.4B license to Merck & Co. and a $5B license to Summit Therapeutics. Prior to his Business Development career, Dr. Pan spent 4 years on protein engineering at Arkema Inc. after obtaining PhD in Chemistry from Stony Brook University.

Alan Phan, CISSP, CISA, CIPT, CDPSE

Vice President - IT Audit
Chubb

Alan Phan is a Vice President of IT Audit at Chubb leading their Infrastructure and Security Audit Team globally. He has 15+ years of IT experience around privacy, security, and cyber risk management working in the corporate environment and as a consultant. As a strong supporter of diversity, equity, and inclusion, Alan serves on multiple boards and committees to help influence and shape organizational culture. When not working, Alan enjoys staying active playing basketball and golf. He also enjoys a good Netflix binge and spending quality time with his family of four children, a wonderful wife…and a dog.

Reena Philip, Ph.D.

Associate Director for Biomarkers and Precision Oncology, Oncology Center of Excellence
FDA

Dr. Philip currently holds the position of Associate Director, Biomarkers and Precision Oncology in Oncology Center of Excellence (OCE), FDA. Prior to this, Dr. Philip was the Director of the Division of Molecular Genetics and Pathology, at Center for Devices and Radiologic Health at the FDA for almost 9 years. At the FDA, she leads OCE's efforts surrounding cancer biomarkers and diagnostics both internally and for external outreach and collaboration. She works on policy and guidance on tumor biomarkers and diagnostics, providing advice, consultation, and assistance on precision oncology matters to the other Centers in the Agency.

Matthew Robinson, Ph.D.

Chief Technology Officer
Immunome

Matthew Robinson, PhD, joined Immunome in March 2016 and brings over 20 years of experience in the fields of antibody engineering and therapeutic development. Prior to joining Immunome, Dr. Robinson was a faculty member in the Developmental Therapeutics Program at Fox Chase Cancer Center. His academic research laboratory focused on the development of antibody-based molecules for the detection and treatment of cancer. His work was funded through grants from the NIH, American Cancer Society, and Department of Defense, as well as by industry partners. Matt earned an M.S. in biochemistry and Ph.D. in genetics from the University of Rochester School of Medicine & Dentistry and then went on to perform post-doctoral studies at Yale University School of Medicine.

Rob Sederman, M.B.A.

Co-Founder and CEO
Ambit Inc

Rob Sederman brings 30+ years of experience in strategy and analytics consulting, as well as two prior start-ups with successful exits to his role as CEO. These experiences and a heavy focus on the rare disease space over the last 5+ years contributed to Rob's role as a founder of Ambit and setting the strategy for our products and services. Rob has a BS from the US Air Force Academy and an MBA from Harvard Business School. Originally from Falmouth, Massachusetts, Rob now resides in Morristown, NJ.

Serina Shi, CFA,CAIA

Financial Advisor
Morgan Stanley

Serina Shi is a Financial Advisor at Morgan Stanley Wealth Management. Before joining Morgan Stanley in November 2021, she worked at Envirovest Inc, leading global business development efforts and raising capital for environmental and ESG investment opportunities. In this role, she collaborated with various financial institutions, including IFC, MS Sustainable Investments, and family offices, to source ESG deals worldwide. Before Envirovest, Serina worked as a director and investment analyst at Prudential Global Investment Management for over seven years. In that role, she conducted due diligence, recommended and monitored investment managers for Prudential's institutional clients, and performed deep qualitative and quantitative analysis on traditional and alternative investment teams worldwide. Before that, she comes from PNC. Serina has an MBA from Drexel University and a Bachelor of Economics in International Finance from Fudan University. Her credentials include Chartered Financial Analyst (CFA) and Chartered Alternative Investment Analyst (CAIA). Her investment and analytical skills and deep understanding of the financial industry can help clients grow their financial assets and achieve their life goals. Additionally, her bilingual skills in English and Chinese and her cultural sensitivity can be valuable assets in client interactions.

Michael Song, M.D., M.S.

Executive Medical Director
Takeda Pharmaceutical Company

Experienced physician scientist in clinical stage compounds development with over 20 years' experience in biologics and cell therapy clinical development within large pharmaceutical

corporations. Experiences in clinical development, clinical operations, medical affairs, regulatory/licensing, product development, commercialization and market access. In-depth knowledge of clinical trial design, execution, global regulatory submission and approval. Strong cross functional team leadership and project planning skills. A passionate leader to create a work environment which allows everyone to succeed.

Marion Stamp-Cole, M.B.A.

Director
Pharmaron US Clinical Services

Marion Stamp-Cole is the Director of Clinical Services at Pharmaron US Clinical Services located in Baltimore Maryland. Marion has over 35 years of Global Clinical operations leadership experience in strategic planning, Decentralized Trials management, and BD/sales/marketing in both pharmaceutical and CRO companies. Prior to joining Pharmaron Clinical Services, Marion was a senior executive at several well-known industry companies, including IQVIA, PRAH, PPD, Pfizer, Pharmacia, and The Upjohn Co. Marion was also a subject matter expert consultant for various pharmaceutical companies; Merck, Lilly and Pfizer. She received her BS in Chemistry from Nazareth College and MBA in International Business Management from University of Phoenix.

Jianxin Sun, Ph.D.

Professor of Medicine and Associate Director in the Center of Translational Medicine
Thomas Jefferson University

Jianxin Sun, PhD, is a Professor of Medicine and Associate Director in the Center of Translational Medicine at Thomas Jefferson University. His lab studies endothelial dysfunction and its relevance to cardiovascular diseases and chemotherapeutics-induced cardiotoxicity. His recent work has been focused on endothelial cell mechanotransduction and regulation of vascular inflammatory pathways in response to a variety of dynamic mechanical stimuli, including hemodynamic shear stress, stretch and stiffness, and how this knowledge can be translated for the development of novel therapies against cardiovascular diseases and vascular inflammation. Dr. Sun received his PhD from Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, and completed his postdoctoral training at Harvard Medical School.

Mark Tang, Ph.D., M.P.H, M.B.A.

Managing Director
Good Health Capital

Mark Tang is a managing director of Good Health Capital, a healthcare private equity firm with offices in Asia and New York. Mark has over two decades of experience in the field of biotechnology as an entrepreneur, educator, advisor, and investor. He previously worked for investment bank PaineWebber/UBS and Morgan Stanley/Dean Witter. He was formerly a research associate at Rockefeller University and a biotech director at Rutgers Business School. Mark attended the University of California, NYU and Harvard.

Lan Tang, Ph.D.

Director, Business Development
GenScript Probio USA, Inc.

Dr. Lan Tang is the Director of Business Development at GenScript Probio, providing presales consultation on antibody drug discovery, development, process development, and GMP/GMP compliance plasmid and virus services. Lan has 26 years biomedical experiences, with diverse background in academic, hospital, and biotech industries. She holds a medical degree from China, and obtained her Ph.D degree from Carnegie Mellon University. She also had her Postdoc experience in Yale Medical school, specialized on immunoncology.

Weifeng Tang, M.D., Ph.D

Executive Director, Head of Vaccine and Immune, and Neuroscience, Clinical Pharmacology and Pharmacometrics
AstraZeneca

Weifeng received his M.D. from Xiangya School of Medicine and Ph.D. from University of Rhode Island School of Pharmacy. He started his pharmaceutical career in 2000 at Bayer and then joined AstraZeneca in 2007. Within AZ, Weifeng gradually increased his responsibilities over the time. Currently, Weifeng is heading a global clinical pharmacology team to support Vaccine, Immune and neuroscience. As a professionally trained and accomplished physician scientist and clinical pharmacologist, Weifeng has >60 peer reviewed publications.

Jason Uslaner, Ph.D.

VP, Head of Discovery Neuroscience
Merck & Co.

Dr. Jason Uslaner is Vice President, Head of Discovery Neuroscience at Merck. The department is focused on discovering novel treatments for Central Nervous System Diseases, including Neurodegenerative and Psychiatric Diseases, as well as pain using various modalities including small molecule and biologics approaches. The department also collaborates both within and outside of Merck to identify and validate novel targets, as well as to develop biomarkers to help enable and improve clinical execution.

Srinivasan Vairavan, Ph.D

Director, Data Science and Digital Health
Janssen R&D, JNJ

Srinivasan is currently a Director of Data Science and Digital Health in Neuroscience Data Science group at Janssen R&D and he leads several digital health and precision medicine initiatives in neuropsychiatry programs. His expertise is in signal processing and machine learning. Srinivasan joined Johnson and Johnson from Proteus digital health (acquired by Otsuka pharmaceuticals) where he led the data science activities related to smart alerts using medication adherence data and wearable sensor data. Prior to Proteus digital health, Srinivasan was a senior scientist at Philips Research where he was leading analytic activities to predict acute events (such as Acute Respiratory Distress Syndrome, etc.) in Intensive Care Unit (ICU). Srinivasan holds PhD in Biomedical Engineering and his doctoral work focused on development of normative fetal neurological maturational indices based on heart rate patterns and brain patterns during sleep/awake cycles using fetal Magnetoencephalography and fetal Magnetocardiography.

Hong Wang, M.D., Ph.D., E.M.B.A.

Director and Professor, Lewis Katz School of Medicine
Temple University

Dr. Hong Wang received her medical training from JinagXi Medical School, an MS degree from Peking Union Medical University, a PhD degree in Biochemistry from University of Montreal, and an EMBA degree from Fox Business School in Temple University. She did her post-doctoral fellowship and then was a research associate in Harvard School of Public Health from 1996 to 1999. She joined faculty in Baylor College of Medicine as an assistant professor in 1999, moved to Temple University School of Medicine as an associate professor in 2005. She became a tenured professor in 2007 and Laura H. Carnell Endowed Chair professor in 2015 in Lewis Katz School of Medicine (LKSM). She is the Director for the Center for Metabolic Disease Research and was Associate Dean for Research and Interim Chair for the Departments of Microbiology and Immunology at LKSM.
Dr. Wang has strong leadership in cardiovascular science communities. She served in multiple leadership committees for three councils of America heart Association (AHA), including ATVB, BCVS, and FGTB Councils.
Dr. Wang's research focus on molecular mechanism underlying cardiovascular inflammation, atherosclerosis, vascular function, lipid and glucose metabolism. She is a leading scientist in hyperhomocysteinemia (HHcy) – cardiovascular disease research.

Richard (Liqun) Wang, Ph.D., M.B.A.

Founder, Chairman and CEO
Neukio Biotherapeutics

Positions held previously, VP & CTO, Fosun Pharma. Founding CEO of Fosun Kite Biotech, completed tech transfer, registration trial and market authorization application for Yescarta in China (the first CAR-T product) in less than three years. COO of CBMG (Cellular Biomedical Group), managed production and clinical trials of stem cell and CAR-T therapies Head of Operations, GSK R&D Center in China. Director of Alliance, Externalization and Portfolio Management, AstraZeneca Innovation Center China.
Associate Director, Discovery Portfolio and Project Management, Bristol-Myers Squibb USA. Group Leader & Principal Scientist, Procter & Gamble Pharmaceuticals, USA.
Richard received B.S degree in Cell Biology from the University of Science & Technology of China, Ph.D. in Molecular Biology from the University of Maryland, Baltimore and MBA from Xavier University, in Cincinnati. He obtained postdoctoral training at the National Institutes of Health, USA.

Debra Weinstein, M.D.

Vice President - Internal Medicine
Science 37

Dr. Weinstein's involvement in clinical research began in 2002 when she became involved as both a sub-investigator and principal investigator with Visions Clinical Research. In 2007, she founded her own clinical research company, ZASA Clinical Research which has had great success in all aspects of Internal Medicine research. In 2009, Dr. Weinstein co-founded and became the managing member of Orthopedic Research Institute, a company specializing in rheumatologic, orthopedic, podiatric and pain management studies. In 2011, she became one of the founding members of Atlantic Clinical Research Collaborative (ACRC). ACRC operated as multi-disciplinary research company with broad capabilities. Dr. Weinstein currently

devotes all of her time to clinical research. Over the last 21 years, Dr. Weinstein has served as an investigator on over 260 clinical studies. Dr Weinstein joined the team at Science 37 in October of 2017. She is currently serving as Vice President of Internal Medicine at Science 37.

John Wang, Ph.D, D.V.M

Associate Vice President
Eli Lilly

Qiang (John) Wang has been an Associate Vice President and Head of Immunology External Innovation at Eli Lilly since December 2018. Since joining Eli Lilly, John has identified and brought in numerous external innovation opportunities leading to several significant transactions including a $1.1 billion acquisition of Dermira in 2020, which internalized a Phase 3 program (Lebrikizumab) for the treatment of atopic dermatitis. Prior to joining Lilly, John worked at Merck Business Development and Licensing group, Sanofi External Innovation team, and Wyeth Research (Pfizer). While being appointed as an Adjunct Assistant Professor at University of Pennsylvania School of Veterinary Medicine, John started his industry career as a Principal Research Scientist at Wyeth Research (Pfizer) Neuroscience, CVMD and Women's Heath. John obtained a Veterinarian Degree from Qingdao Agricultural University College of Animal Science & Veterinary Medicine, China, a MS in Veterinary Pharmacology from Nanjing Agricultural University, China, and a PhD in Pharmacology from University of London, St George's Hospital Medical School, UK and conducted his postdoctoral training at both Harvard Medical School and Boston University School of Medicine.

Jennings Xu

Senior Director, Janssen R&D Data Science & Digital Health
Janssen Pharmaceuticals

Jennings is a Senior Director for the Data Science & Digital Health team of Janssen Research & Development Global, serving dual roles as the head of Infectious Disease Data Science and as the global data science strategy and portfolio lead for the Asia Pacific region across the portfolio. He works with a team of data scientists, clinicians, and other cross-functional stakeholders across the discovery and development process to identify at-risk patient populations, characterize patient journey, and design and execute clinical trials using A.I., real world evidence, and advanced analytics. His team led the highly impactful Janssen-MIT Covid-19 prediction model that resulted in the Johnson & Johnson Covid-19 vaccine reaching individuals sooner than expected during the pandemic, recognized by winning the IAAA award, being an Edelman award finalist, and receiving the Johnson Award 2021. Prior to Johnson & Johnson, Jennings was Director of Healthcare at Quid, an A.I. / NLP company, and at McKinsey & Co driving transformational pharma, provider, and healthcare supply chain projects. Jennings was a Simons Fellow in Computational Research at the Yale Child Study Center at the Yale School of Medicine and completed his B.A. in Biology at Harvard University.

Bing Yao, Ph.D.

CEO & Chairman
ArriVent Biopharma

Dr. Bing Yao is the Chief Executive Officer and Chairman of ArriVent Biopharma. Dr. Yao is an accomplished executive and scientist with more than 28 years of experience in the biotechnology and pharmaceutical industry. he served as Chairman and CEO of Viela Bio, which he co-founded in 2018. In 2021, Viela Bio was acquired by Horizon Therapeutics for $3.05 billion. Prior to his role at Viela, he served as Senior Vice President of R&D and Head of Respiratory, Inflammation & Autoimmunity at MedImmune and as Senior Vice President, Head of Immuno-Oncology Franchise at AstraZeneca. During his tenure at MedImmune and AstraZeneca, he played key leadership roles in the development and approval of multiple novel biologics for autoimmune, respiratory, and immune-oncology indications, respectively. Prior to joining MedImmune, Dr. Yao led the project team leaders' group for immunology, neurosciences, virology, and metabolism for Genentech, and prior to that, served as Vice President and head of Research and Corporate Officer for Tanox before it was acquired by Genentech. Earlier in his career, Dr. Yao held key roles at Aventis and Amgen. Dr. Yao has authored more than 50 peer-reviewed publications and holds over 20 patents and patent applications

Nick Zhang

Board Chairman and CEO
MEDx Translational Medicine Co., Ltd

With 30 years of drug R&D experience and years of experience in translational science and diagnostics, Nick is now the board chairman and CEO for MEDx Translational Medicine Co., Ltd. Nick was China GM and Corporate SVP for Frontage Lab, and a founding director and executive for Novartis China R&D center. Before that, Nick was a director at US OSI Pharmaceuticals and a manager at Pfizer global R&D center. Nick is now a member of Bayhelix, a global association of Chinese Life Science Business Executives; an invited vice president of Jiangsu Life Science and Technology Association. He is one of 5 founders and deputy director for China Precision Medicine and Companion Diagnostics Consortium. Nick is the recipient of the China Suzhou SIP Leading Talent Award, China Jiangsu Province Entrepreneur and Innovation Talent Award, and China National major talent Award.

Wei Zhou, M.D., Ph.D.

Associate Vice President
Eli Lilly and Company

Wei Zhou is currently Associate Vice President and Head of Oncology, at Lilly Value, Evidence, and Outcomes (VEO). Before that, he was the Executive Director and Head of Oncology at Merck Epidemiology Department, Executive Director at Merck CORE Product Line, Head of Epidemiology Asia Pacific Unit at Merck, Director of Molecular Epidemiology at Pfizer Oncology, and Senior Epidemiologist at Merck. Wei was a Research Fellow/Research Associate/ Research Scientist at Harvard School of Public Health between June 1999 and December 2007. Wei is a Fellow, previous Board Member and Vice President for Finance, and co-lead of the Real-World Evidence Task Force of the International Society of Pharmacoepidemiology (ISPE).
Wei received his MD from West China University of Medical Sciences in 1994 and Ph.D. of Environmental Health from Shanghai Medical University in 1998. He was the recipient of the John E. Fogarty International Training and Research Program. He has published more than 90 peer-reviewed manuscripts and book chapters and served as a reviewer for various international journals. Wei has given numerous presentations and served as chair/co-chair at different international conferences and symposiums. Wei is a well-known expert in the fields of cancer epidemiology, molecular epidemiology, Outcome Research, and real-world evidence research.

Joe Zhuo, Ph.D.

Senior. Director, WWHEOR
BMS

PhD trained health economist with professional experience across federal agency and pharmaceutical industry, specializing in health economics and outcomes research.

Peng Zou, Ph.D.

Director
Daiichi Sankyo Inc.

Dr Peng Zou is a Director of Clinical Pharmacology in the Quantitative Clinical Pharmacology Department of Daiichi Sankyo Inc. He serves as a clinical pharmacology representative for multiple clinical development programs in the Specialty Medicines portfolio. Prior to joining Daiichi Sankyo, Peng was employed by the Food & Drug Administration (FDA) in the Office of Clinical Pharmacology (OCP). While in that role, he reviewed the clinical pharmacology sections over 250 NDA, BLA and IND submissions. Prior to working in the OCP, Peng was in the Office of Pharmaceutical Quality at the FDA, where he reviewed the chemistry, manufacturing, and controls (CMC) sections of more than 70 ANDAs and DMFs. He has been a contributor to the scientific community, with 60 journal publications and being named on two patents.

Track Leads & Session Chairs

David Cragin, Ph.D., DABT

Senior Director
Teva Pharmaceutical

Dr. Dave Cragin is Senior Director of Product Science in the department of Environment, Health, Safety and Sustainability at Teva Pharmaceutical. In this role, he helps lead efforts to protect employees and the environment. His team assesses the potential hazards of drugs and drugs intermediates at manufacturing sites and for quality purposes. They also conduct life cycle assessments and develop risk-based limits for health and environmental purposes. Previously, he served in Quality as a Director of Complaint Management and in other roles for Merck & Co. For many years, he has taught risk assessment and critical thinking for the *University of the Science*s, Philadelphia, *Peking University*, and *Beijing Normal University*. In addition, he has taught risk communication across the globe. He speaks Chinese and is knowledgeable in many languages. Dr. Cragin is a Trustee of the *Toxicology Education Foundation*, is Past-President of the *Mid-Atlantic Society of Toxicology*, and a Councilor for the *Philadelphia Association for Critical Thinking.* He received his Ph.D. in Pharmacology and Toxicology from *University of California, Davis,* his B.S. in Zoology from the *University of Rhode Island*, and is a Diplomate of the *American Board of Toxicology*.

Dong-Jing (DJ) Fu, M.D., Ph.D.

Senior Director, Clinical Development,
Janssen R&D, LLC

Dr. Fu is a Senior Director in Neuroscience Clinical Development at Janssen Research and Development. Currently she is the Clinical Leader of the intranasal esketamine development program in patients with treatment resistant depression and major depression at imminent risk for suicide. She is also a clinical leader for several compounds in early stage of development for neuropsychiatric disorders. Since joining Johnson & Johnson in 2005, Dr. Fu has worked on pivotal studies for the treatment of depression, suicidality, schizophrenia, and schizoaffective disorder. She has held positions within Janssen R&D and Medical Affairs directing global clinical trials, leading pharmacogenomics projects in psychiatry, and overseeing a program to support independent medical education in psychiatry. Dr. Fu had prior positions with Eli Lilly and Sequenom involving research and technology development for precision medicine. Dr. Fu has authored publications focused on clinical and pharmacogenomic research of psychiatric diseases and treatments, scale validations, and technology development. Dr. Fu received her PhD in biochemistry from Boston College and a MD from Beijing Medical University.

Hangfei Fu, Ph.D.

Equity Research Associate
TD Cowen

Hangfei Fu, Ph.D. joined Cowen as a Biotech Equity Research Associate in 2021. Dr. Fu received her Ph.D. degree in Biomedical Sciences from Temple University Lewis Katz School of Medicine. She published 10+ peer-reviewed articles during her Ph.D. program. Dr. Fu has volunteered at SAPA for 9+ years and now serves as Finance Director for SAPA-GP.

Dennis M. Gross, M.S., Ph.D.

Chief Executive Officer
Pennsylvania Drug Discovery Institute

Dennis M Gross, MS, PhD is the CEO for the Pennsylvania Drug Discovery Institute. He is also teaching faculty in the Jefferson College of Life Sciences and Adjunct Associate Professor of Pharmacology & Experimental Therapeutics in the Sidney Kimmel Medical College of Thomas Jefferson University (TJU). In addition, he is Corporate Faculty at Harrisburg University of Science & Technology and Professor (with Distinction) of Experimental Therapeutics and Medicinal Chemistry at the Baruch S. Blumberg Institute. Previously, he was the Associate Dean at TJU for Program Development and Assessment and Director for the Professional Science Masters Programs. Prior to this, he was at the Merck Research Labs for 29 years, retiring in 2006 as Senior Director and Head of Business Operations with overall responsibilities for capital planning and facility operations in Pennsylvania, California, and Massachusetts. He was also responsible for lab projects and operations oversight at MRL sites in Canada, Japan, Italy, and the UK. In his Merck career he held several positions ranging from bench scientist to M&A activities and liaison for basic research and clinical drug development in Japan working with Banyu Pharmaceuticals. During his tenure at Merck, he also served as Adjunct Professor of Global Logistics in the School of Business and Industry of Florida A&M University. He has worked with the CSIS on policy issues relating to biological weapons of mass destruction.
He received his BA and MS from California State University and his PhD from UCLA pursuing a postdoctoral fellowship

in pharmacology at the Tulane University School of Medicine. He has also participated in executive education programs at Wharton, MIT, Tufts, and Harvard University Schools of Law and received NIMS and ICS certification from FEMA. He served as the National Co-Chair for the Biotechnology Entrepreneur Bootcamp. He is a member of the American Association for Pharmaceutical Scientists, American Chemical Society, History of Science Society, International Society for Pharmaceutical Engineering, Sigma Xi, and SAPA-GP.

Evelyn Guo, M.D., M.B.A

Medical Director
Astrazeneca

Dr. Evelyn Guo is Medical Director of Rare disease unit clinical development department at Astrazeneca. In this role, she helps lead efforts to bring new medication to patients through FDA approval process. Previously, she served in auto immu disease clinical development for Eli Lilly Co.

Jun He, Ph.D

Assistant Professor, Department of Pathology and Genomic Medicine
Thomas Jefferson University

Dr. Jun earned her Ph.D degree at Cell Biology and Development Program at Thomas Jefferson University in 2013. She was the recipient of a prestigious NIH/NCI K99/R00 award which helped her to achieve independence and set up her own lab. Dr. He has 15 years of experience in epigenetic regulation, oncogenic signaling pathways, and tumor microenvironment in regulating cancer development, angiogenesis, metabolism, and therapeutic resistance. Dr. He is currently a Principle Investigator in multiple NIH R01 grants, and has served as Ad-hoc proposal reviewer in NIH study sections since 2021. Dr. He is an active volunteer in SAPA-GP events. She served as the session chair and track lead in SAPA-GP AC2022 and CGT2022 conferences, respectively.

Kevin He, M.B.A.

Director of Business Operations
uBriGene

Kevin is a Director of Business Operations at uBriGene Biosciences, a global CDMO for cell and gene therapy. Kevin brings over 15 years of sales and marketing experience in the financial, industry gas, and biotech industries. He is specialized in collaborating with executive teams on strategy development and in solving complex business problems. He has a proven track record of increasing the sales pipeline and contributing to the company's top and bottom-line growth.
Kevin grew up in Philadelphia and earned a bachelor's degree and an MBA from Penn State University at University Park, PA. Kevin is a very active volunteer in the Philadelphia community. Currently, he serves as the Chief Operating Officer at the National Association of Asian American Professionals (NAAAP) – Philadelphia Chapter, where its mission is to provide a professional development platform for the Asian American professionals and to serve the local Asian community. Kevin is a VP of Sponsorship at CBA-GP. He is passionate about diversity and inclusion, he has founded and chaired an Employee Resource Group (ERG) for Asian American employees while at Air Products. He has also co-founded a mentoring program for a local elementary school in2009, and still an active mentor.

Yufeng Li, Ph.D.

Executive Director, Clinical Development
Qilu Pharma

Yufeng Li, PhD, is currently Executive Director of Clinical Development at Qilu Pharma, based in Philadelphia, PA. Yufeng graduated from Shanghai Jiao Tong University, and obtained PhD training at UT MD Anderson Cancer Center at Houston, focusing on cancer immunology and immunotherapy. Subsequently, he spent many years at GSK to discover and develop medicines for cancer patients. Prior to Qilu, Yufeng has also served China biotech companies (Ascentage and Transcenta) to oversee their US and global clinical programs. Yufeng is active for community based volunteer activities, including serving important roles in organizations such as Sino-American Pharmaceutical Professionals Association – Greater Philadelphia (SAPA-GP). He has established the Pharma360° training program.

Qingqin S Li, Ph.D.

Senior Director, JRD Data Science, Neuroscience Data Science
Janssen R&D, LLC

Qingqin is a Sr. Director in Janssen Research & Development, LLC, JRD Data Science, Neuroscience Data Science. In her current role, she is responsible for driving end-to-end scientific strategy across the Neuroscience Data Science portfolio and serves as the Data Science and Digital Health Lead for the Aticaprant, P2RX7, and mGlu2PAM932 Compound Development Teams. In her nearly 25 years working in data science in the pharmaceutical industry, Qingqin has led internal research programs and external collaborations with leading academic and industry partners, integrating diverse data types including genetics, multi-omics, digital, and RWE. At Janssen, she has driven pioneering Digital Health observational clinical studies for relapse prediction in major depressive disorder and schizophrenia. Qingqin is a strong advocate for consortium-driven big data efforts. She serves as Janssen's representative to the Psychiatric Genome Consortium (PGC) and works closely with PGC, International Suicide Genetics Consortium (ISGC), International League Against Epilepsy (ILAE), and the Alzheimer's Disease Neuroimaging Initiative (ADNI) to incorporate Janssen data and genetic association/omics study results into consortium wide meta-analysis efforts to increase discovery of novel genes for mental illnesses and neurodegenerative conditions. She has published 70+ peer-reviewed articles. Previously Qingqin led a team in Pharmacogenomics and Neuroscience Biomarkers, where her group was among the first in the company to implement large-scale candidate gene and genome-wide association studies for gene discovery, together with Johnson & Johnson Technology (JJT) to establish the first high-performance computing environment to enable next-generation sequencing data generation, gene discovery, and precision medicine. Prior to joining Janssen in 2002, Qingqin was a Principal Research Scientist at Eli Lilly & Company supporting Oncology computational biology and driving transcriptome profiling platform expertise across therapeutic areas (TAs) and functional areas. She has held academic positions at the University of Chicago, Harvard Medical School/Massachusetts General Hospital, and Emory University. She received a bachelor's degree in Biochemistry from Fudan University, a Ph.D. in Biochemistry and Molecular Biology from Emory University, and an M.S. in Computer Science from the University of Chicago.



Yali Liang, M.D., M.S., M.P.H.

Director of Clinical Pharmacology & Pharmacometrics
Jazz Pharmaceuticals

Yali is a Director in Clinical Pharmacology & Pharmacometrics at Jazz Pharmaceuticals. Currently she is the pharmacometrics lead for Rylaze, Lurbinectedin and overseeing pharmacometrics aspect of early development agents for oncology and neuroscience portfolios at Jazz. Prior to joining Jazz, she worded at Bristol-Myer Squib as a clinical pharmacology lead focusing on immune-oncology therapeutic agents. Prior to BMS, she worked at Global Pharmacometrics at Pfizer. Yali has over 13 years of drug development experience in pharmaceutical industry and has contributed to the successful approval of Opdualag (nivolumab and relatlimab combination therapy), Opdivo, nivolumab-ipilimumab combination therapy, avelumab, ertugliflozin, ALO-2 etc. Yali holds a MS in Pharmacometrics from University of Maryland, MS in Pharmaceutical Science from University of Kentucky, and a MD from Tongji Medical University.

Bill Lu, M.B.A.

Founder and Principal
Forerun Advantage

Bill Lu is the founder and principal of Forerun Advantage, a consultancy helping Chinese biotech companies to establish US operations. Previously, he worked for Emory University School of Medicine developing digital medicine solution and clinical trial management system. Bill Lu has volunteered at SAPA-GP since 2019 and currently serves as head of PR for SAPA-GP.

Tao Niu, Ph.D.

Associate Director, Clinical & Quantitative Pharmacology
Vertex Pharmaceuticals

Tao Niu has broad experience in clinical & quantitative pharmacology for rare diseases, particularly in viral and non-viral in vivo gene therapy. He is currently the Clinical & Quantitative Pharmacology lead for a LNP encapsulated mRNA therapy in cystic fibrosis at Vertex. He also leads the Clinical & Quantitative Pharmacology efforts in Myotonic Dystrophy 1 at Vertex. Prior to Vertex, Tao was the pharmacometrics lead for Wilson's disease (in vivo replacement gene therapy using AAV) at Pfizer. Tao also has extensive experience in regulatory submissions and is a key driver in the approval of two drug products (TRIKAFTA® in

cystic fibrosis and NGENLA® in pediatric growth hormone deficiency). He is a subject matter expert in biologics PK assay and immunogenicity. He is currently representing Vertex in the IQ consortium immunogenicity working group and the nucleic acid working group. Tao holds a PhD in Pharmaceutics from University of Houston, an MS in Pharmacometrics from University of Maryland, a BS in Pharmaceutical Sciences from Shenyang Pharmaceutical University.

Helen Sun, MHRM, SPHR

Head of human resource
Exegenesis Bio Co.

HR professional with 10+ years of work experience and a deep understanding of unique challenges that different sized Pharma/Biotech/CDMO organizations may face; SME on talent acquisition, performance management, employee engagement, and leadership development.



Leon "Jun" Tang, Ph.D.

Founder / Advisor
InScienceWeTrust BioAdvisory, BioSpark Group

Leon 'Jun' Tang, PhD is the founding partner of InScienceWeTrust BioAdvisory, a consulting firm that advises biotech companies in the US and APAC of creative business development via his expertise in public relations and the creation of scientific advisory board. He is also a scientific advisor to Mianus Capital, a boutique US-based private equity fund focused on healthcare investment. As of today, Dr. Tang has involved investment and BD transactions with accumulative value of ~$1.2 billion.

Dr. Tang is an advisor to BioSpark Group, a Boston-based nonprofit primarily consisting of Asian professionals in biotech and biopharma sectors around the world. He also founded and has been managing InScienceWeTrust Community, an Asian-focused community of ~1,000 executives and professionals primarily from the US and China, and other geographic locations.

Previously, Dr. Tang was a senior director of BD at Shanghai Henlius Biotech, a public biotech listed on Hong Kong Stock Exchange with 5 marketed biologics, from 2020 to 2022, leading the search and evaluation team; a biotech analyst at Barclays Investment Bank from 2019 to 2020; a senior manager/senior analyst at the philanthropic venture fund of Cancer Research Institute of New York from 2017 to 2020.

Dr. Tang has published 50+ academic papers, including many in Nature Reviews Drug Discovery, Lancet Oncology, Science Translational Medicine, Nature Communications, Science Advances, PNAS, etc. Dr. Tang received a certificate of medical writing and passed CFA level I.

Dr. Tang received his Bachelor of BME from Tianjin University, Master of Science from Nankai University, PhD in biomedical sciences from Icahn School of Medicine of Mount Sinai, and postdoctoral training at Memorial Sloan Kettering Cancer Center.

Jin Wen, Ph.D.

Senior Scientist, Analytical Development, CMC
Spark Therapeutics

Jin is a Senior Scientist at Spark Therapeutics, where she leads the development of mass spectrometry methods and oversees the review of outsourced data. She also supports AAV process development, product characterization, and quantification of process-related impurities. Prior to joining Spark, Jin worked as an MS Subject Matter Expert and Analytical Development Project Lead at Teva Pharmaceuticals. Jin earned her Ph.D. in Chemistry from The Ohio State University, where she specialized in designing combinatorial peptide libraries for drug discovery and cyclic penetrating peptide design for intracellular delivery.

Di Wu, Ph.D.

Senior Scientist, Biopharmaceutics, Sterile Special Products
Merck & Co.

Dr. Di Wu is currently the project manager of SAPA-GP and a Senior Scientist in Biologics Development and Biopharmaceutics at Merck. She joined Merck in 2020 where she serves as a biopharmaceutics expert in oral and parenteral drug development. Prior to that Di was an Orise Fellow in the division of Biopharm, OPQ in FDA, where she worked on PBPK modeling for weak acid drugs and IVIVC. Di received her PhD in Pharmaceutical Sciences from Temple University, focusing on drug delivery systems and a Bachelor degree from China Pharmaceutical University.

Shuang "Steve" Wu, Ph.D., M.S.

Engagement Manager
Ambit Inc.

Shuang "Steve" Wu, PhD, MS, is currently an Engagement Manager at Ambit Inc. Steve leverages his deep knowledge and understanding in life sciences as well as his training in statistics and analytics to help clients anticipate trends and break through strategic barriers. Steve has 5 years of life science consulting experience with a focus on commercial strategy and analytics, with project experience spanning claims data analysis, patient journey analysis, patient finding, patient/HCP segmentation, statistical modeling, opportunity assessment, sales forecast, qualitative/quantitative market research, and secondary research. Steve was a Senior Associate at CRA prior to joining Ambit Inc. Steve had been an active Executive Committee Member of the Sino-American Pharmaceutical Professionals Association – Greater Philadelphia Chapter (SAPA-GP) from 2014 to 2018. His role at SAPA-GP evolved from a visual artist to a young leader, where he contributed consistently to the success of multiple flagship events, promotion of pharmaceutical and biomedical sciences and the career development of life sciences professionals and students. Steve received his MS in Biostatistics from Columbia University, and his PhD in Cell and Molecular Biology from Rowan University.

Haichen Yang, M.D., M.A., M.B.A.

Current President for SAPA-GP
Vice President, Clinical Research
Amicus

Dr. Yang is the current President for SAPA-GP. She is an accomplished pharmaceutical executive and drug development expert with 28+ years of experience in neurology, psychiatry, pain, and metabolic disorders. She has led many successful global clinical development programs, including several resulted in new drug and indication approvals, such as Fycompa®, Keppra®, and Luvox CR®. Dr. Yang is a Vice President of Clinical Research at Amicus Therapeutics, leading small molecule and gene therapy clinical programs. She was previously a Vice President at ICON plc, where she provided strategic consulting services on drug development to top executives of biotech/pharma companies worldwide, acted as client's Chief Medical Officer, and conducted asset due diligence for major biotech investors. Before that, she worked for Eli Lilly, Solvay, UCB, and Eisai. Dr. Yang is a highly accomplished researcher, with publications including 2 book chapters, 40+ peer-reviewed journal articles, 120+ international conference posters, and several industry thought leadership articles. She is frequently invited to speak and holds committee memberships of multiple drug development societies. She is also a board member of a US investment firm. Dr. Yang received her medical degree from Peking University Health Science Center (formerly Beijing Medical University) in China. She has a Master's degree in molecular biology from Indiana University Bloomington and an MBA degree from Temple University Fox School of Business.



Lixia Yao, Ph.D.

Principal,
Polygon Health Analytics LLC*;*
Adjunct Associate professor,
Department of Health Services Administration and Policy,
Temple University

Lixia Yao, PhD, is the visionary behind Polygon Health Analytics LLC, a company that provides comprehensive real-world data solutions. Prior to her entrepreneurial pursuits, Dr. Yao served as the Director of Real-world Data Analytics and Innovation at Merck and held a position as an Associate Professor of Biomedical Informatics at Mayo Clinic. She earned her PhD in Biomedical Informatics from Columbia University in 2010 and has a wealth of experience in the industry and academia, having previously worked as a Principal Investigator at GlaxoSmithKline and an assistant professor at the University of North Carolina at Charlotte. As a leader in her field, Lixia has published over 60 peer-reviewed articles in renowned biomedical conferences and journals such as Nature Biotechnology and Genome Research. Her H-index is 17. She is also the recipient of Career Development Award in Biomedical Informatics (K01) from the National Library of Medicine for 2016-2019, a Fellow of American Medical Informatics Association (FAMIA), and the Chair of the AMIA KDDM working group from 2020-2022. Additionally, she is an adjunct associate professor in Department of Health Services Administration and Policy at Temple University.

Yang Yuan, Ph.D.

Current President-Elect for SAPA-GP
Associate Director, Nonclinical Research & Development
Jazz Pharmaceuticals

Yang Yuan is currently the President Elect of SAPA-GP (2023-2024) and Associate Director in Nonclinical Research & Development at Jazz Pharmaceuticals. She works as a nonclinical team lead in global drug discovery and development team. She also serves as Subject Matter Expert on Due Diligence teams at Jazz Pharmaceuticals. Prior to joining Jazz, she worked as Senior Principal Scientist at Bristol Myers Squibb and DuPont/FMC as technical leader in global regulatory sciences group with increasing responsibilities. Yang has received her Ph.D. in medicinal chemistry with a focus on analytical chemistry from College of Pharmacy, University of Illinois Chicago. She has served as chair of Delaware Valley Mass Spectrometry group from 2013-2016. She actively chairs scientific conferences of ACS/AGRO and ASMS. She has contributed over 20 publications and frequently

given presentation and invited seminars in scientific conference. She serves as reviewer to scientific journals such as Journal of Pharmaceutical Analysis, Chromatographia, Journal of Agricultural and Food Chemistry. At BMS, she led the global business insights and analytics group in PAN Asian Network.

Xinjun Zhang, Ph.D.

Associate Principal Scientist
Merck & Co.

Xinjun Zhang currently is an Associate Principal Scientist in Neuroscience Discovery Department at Merck. Since joining Merck in 2018, he has worked on identifying and validating new drug targets for neuropsychiatric and neurodegenerative diseases, developing novel electrophysiological and molecular platforms to support neuroscience drug discovery. He is also a co-lead at Merck West Point LINK (Leveraging Internal Networks & Knowledge) team. Xinjun was a research associate at Memorial Sloan-Kettering Cancer Center previously. His research focused on studying the functional connectivity and organization during neural development. He has published more than 15 research papers in top-tier journals. Xinjun received his PhD in neurobiology from Fudan University. Xinjun is also an enthusiastic volunteer serving multiple organization to plan and coordinate events on pharmaceutical science and healthcare communications among different institutions. He co-leads the SAPA-GP 2023 Annual Conference and leads the IT team at SAPA-GP.

Ying-Ying Zhou, Ph.D.

Senior Principal Scientist,
Nonclinical Drug Safety
Merck & Co

Dr. Ying-Ying Zhou is a Senior Principal Scientist in the Nonclinical Drug Safety at Merck. She had the privilege of working for academic (Columbia University and NYU), government organization (NIH) as well as industry (Schering-Plough and Merck). During her 20+ year career in industry, Ying-Ying has established the new safety pharmacology lab and led several groups to develop various regulatory-required as well as investigative assays to support R&D. One of her roles is to oversee compound development from a wide range of therapeutic areas and modalities through the entire process as a nonclinical safety representative. She has also actively participated in in-licensing compounds as well as out-licensing activities. As an experienced investigator, she has visited and evaluated candidate CROs and functioned as study monitor for outsourced nonclinical safety studies too. Furthermore, Ying-Ying is the China Liaison and has been heavily involved in developing China strategy, building partnerships with China functional groups, driving increased communication and interaction with China regulatory bodies as well as industrial consortiums.

康龙化成
PHARMARON

Phone:+1 240-704-3705
pcs.bd@pharmaron.com
www.pharmaron.com

Pharmaron Clinical Services

Pharmaron Clinical Services (PCS), located in Piscataway, New Jersey, is dedicated to providing high-quality clinical development services globally. Our clinical services team has over 3,500 employees worldwide.

Capabilities
- Biometrics
- Regulatory Affairs
- Medical Affairs
- Clinical Operations
- Bioanalytical Lab Testing
- Pharmacovigilance
- Technical Staffing
- Dual Registration

Solutions
- Innovative Drug Development
- Medical Device and Diagnostics
- Functional Service Partnership (FSP)
- Early Phase Oncology Product Development

Pharmaron is a premier R&D service provider for the life sciences industry and has invested in its people and facilities and has established a broad spectrum of R&D and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products.

AlpalifeBio

AlpaLife dedicates to novel nanobody/VHH discovery and GPCR production and evaluation for your interest targets

AlpaLifeBio provide customized services for nanobody drugs R&D at various stages, such as, nanobody/VHH discovery, humanization, affinity maturation, and cell based function evaluation. We are a biotech company for discovery and production and sales of alpaca nanobodies and GPCRs and other important membrane proteins for support customer related drug development.

Nanobody Discovery

Alpaca immunization - Library construction - Sequences screening - BLI affinity detection - Humanization and affinity maturation

Protein Production

Prokaryotic - Yeast - Insects - Mammalian

Anti-Tag VHH Beads

Flag - HA - GFP -MYC - mCherry - Mouse - Rabbit

AlpalifeB Inc
299A Washington Street,
Woburn, MA 01801 USA

Toll-free Phone: 1-877-512-8263; Fax: 1-617-336-7451
Office Phone: 1-617-383-9901 Ext 800.
Email: contact @alpalifeb.com
Website: www.alpalifeb.com

GemPharmatech

One Stop Solution for Biomedical Research
World's Largest Collection of Genetically Engineered Mouse Models (GEMMs)

Our professional and experienced team of scientists provide top quality service for our clients, while our extensive mouse resources offer humanized mice, immunodeficient mice, and disease models, which support a wide range of studies in the fields of oncology, autoimmune, neurodegenerative, metabolic and rare diseases. GemPharmatech is committed to expediting biomedical discovery and drug development.

HIGH-QUALITY SERVICES

Advanced technology platform for custom model generation
Professional drug screening service platform
Germ-free and translational microbiome research platform

LARGEST MODEL RESOURCES

Largest GEMM library with **22,000+** models
6,000 new GEMM generation capacity/year
Best technology for your needs with 20+ years of experience (CRISPR/Cas9, Transgenic)

LEADING CAPABILITIES

14 years of AAALAC accreditation
30,000+ m² non-GLP experimental facilities
230,000+ SPF and germ-free mouse housing facilities
Global presence with 7 operational sites in China and the US



GemPharmatech | sales@gempharmatech.us | +1 888 899 5899 | https://en.gempharmatech.com

BrainVTA | Genevoyager

One-stop
CRO / CDMO for Viral Vector Gene Therapy

CDMO services

One-stop CDMO services for AAV vector gene therapy using the One-Bac 4.0™ platform with high infective activity, high yield, full-capsid ratio, high stability, and a single batch capacity up to 1E+18vg.

CRO services

- Custom high-throughput virus services
- Gene therapy drug development and evaluation
- Gene therapy virus quality analysis method development
- High-throughput neutralizing antibody detection
- Oncolytic virus services
- Animal model construction services

Viral vector technology for life sciences

- Design & clone target genes
- 3,000+ Pre-made AAV
- AAV/LV packaging services ranging from small-scale to large-scale
- Pre-made transsynaptic tracing viral vectors

www.brainvta.tech | www.genevoyager.com hui.wang@genevoyager.com | sales@brainvta.com +1 (215) 205-6963

Moving You Forward

BIODURO-SUNDIA

Why You Should Choose Us?

We are your Trusted Global Contract Research, Development and Manufacturing Outsourcing Solutions Provider (CRDMO)

20+ YEARS OF CTM AND COMMERCIAL MANUFACTURING
PIONEERS IN AMORPHOUS SOLID DISPERSION
UNIQUE MANUFACTURING CAPABILITIES ON THE WEST COAST
15+ YEARS OF RETAINED EMPLOYEES

Discovery » **Development** » **Manufacturing**

www.bioduro-sundia.com

Where life-changing meets life-defining.

This is where transformations happen.

Bristol-Myers Squibb Company is an Equal Opportunity Employer M/F/Veteran/Disability/Sexual Orientation/Gender Identity.

Opportunities with Bristol Myers Squibb

Whether in a scientific, business or supporting role, there's no better place to do some of the most interesting and meaningful work of your career.

Interesting and Meaningful Work

You'll be inspired every day as you and your colleagues discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. But the work you do at BMS goes beyond medicine. It will transform patients' lives—and your career—while advancing health for people of all backgrounds around the world.

Opportunity to Grow

With a mission as impactful as transforming patient's lives, you'll be exposed to growth opportunities that are uncommon in scale and scope. With our emphasis on inclusion and engagement, you'll experience dynamic support and unique resources to drive your career forward.

A High-Achieving Team

You'll join a team rich in diversity of experiences, perspectives, and backgrounds, bonded by a shared purpose and values of passion, innovation, urgency, inclusion, and integrity. Our colleagues embrace this open and accessible culture with the same enthusiasm as any other business objective, making the team that much stronger and unified.

Explore opportunities:

Visit **careers.bms.com** to search and apply

Read **Career Stories** from our team

Benefits

We offer competitive benefits and compensation to help each employee grow and thrive. Your work and achievements contribute to transforming patients' lives and BMS designs employee packages to bring out your best.

Explore our Benefits

People and Business Resource Groups (PBRGs)

Our eight PBRGs empower members to be business leaders, add value through the execution of business plans, and accelerate leadership development. They are open to our entire global workforce and membership is growing.

12,500	104	43
members	chapters	countries

Bristol Myers Squibb™

Your One-stop CDMO-Plus Service Provider for Cell & Gene Therapy

uBriGene

About: *uBriGene Bioscience Inc. is a leading contract development and manufacturing organization (CDMO), specializing in development and application of cell and gene therapy technologies. uBriGene provides clients with end-to-end cell and gene therapy support.*




Visit our website & LinkedIn

Protheragen

Protheragen Actively Seeks Collaborations and Recruits Talents

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. We serve as a global business development partner for biotech/pharmaceutical companies and have built close relationships with many investment companies. To further our development, part of our strategies require us to constantly seek high-quality novel drug research and development programs that are open to collaboration opportunities.

Relying on strong industry resources and connections built up throughout the years, Protheragen welcomes partnerships in the following structures:

- **Equity Investment**
- **Intermediary Service**
- **Project Incubation**

As a non-traditional pharmaceutical company, Protheragen is searching for talented and self-motivated senior research scientists to fill the new space with innovative technologies and enthusiastic attitude. We will:

- **Help you become an entrepreneur**
- **Offer a competitive salary and benefit package**
- **Provide work visa sponsorship**

Tel: 1-516-765-9461
E-mail: info@protheragen.com
Address: Room 1, 2200 Smithtown Avenue, Ronkonkoma, NY 11779-7329, USA

Get in Touch
www.protheragen.com

Map


GLADWYNE
Frazer
BRYN MAWR
Devon
BERWYN
Ardmore
STRAFFORD
Paoli
Haverford
Kiosk
MALVERN
Centennial Ballroom III
EXECUTIVE BOARDROOM
ST DAVIDS
Centennial Ballroom II
Centennial Ballroom I
WAYNE
VILLANOVA
Grand Ballroom
Main Entrance